Ryan Allway | Investerms.com

SpeakEasy Cannabis Club Ltd. Engages CFN Media to Develop New Investor Audience

Written by Ryan Allway on Apr 03, 2018

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that SpeakEasy Cannabis Club Ltd. (CSE: EASY) (“SpeakEasy”), has commenced to trade on the Canadian Securities Exchange under the symbol EASY.

“SpeakEasy is the latest Canadian LP applicant to go public trading on the Canadian Securities Exchange (CSE)”, said Frank Lane, President of CFN Media. “The Company is headed by chairman Merv Geen who brings unmatched farming and agricultural experience to SpeakEasy. Mr. Geen served as Chairman of Sun-Rype Products, one of Canada’s most recognizable brands prior to its sale to the Pattison Group. “The company is disrupting the cultivation model by aggregating British Columbia’s best craft growers under one umbrella to produce the highest quality cannabis targeted at the highly sought after millennial recreational market”. SpeakEasy is leveraging three generations of farming experience and the largest land package of LP in Canada with 290 acres of the best agricultural land in British Columbia’s Southern interior region; known as the Napa Valley of weed country.” Please visit www.speakeasygrowers.com for more information and to register for corporate updates.

SpeakEasy has submitted its extensive evidence package on its fully completed 10,000 square foot facility to Health Canada. This is the final step in order to obtain a production license under Section 35 of the ACMPR. This package included documentation, detailed photos and video, facility design packages and the ability to demonstrate product storage, security, monitoring of access and record keeping.

SpeakEasy has commenced construction on its phase 2 expansion which will be a state of the art 80,000 facility that includes growing, extraction and genetics labs that will be capable of producing more than 10,000 kg annually.

“Over the last year we have worked closely with Health Canada throughout this process and we are excited to have cleared this important milestone on the way to becoming a licensed producer,” said Marc Geen, SpeakEasy’s President. “I am so proud of our team and the work they have done, particularly in the past four months. We are confident our evidence will meet and exceed the requirements in the upcoming review and we will achieve our goal of becoming a licensed producer under the ACMPR.”

SpeakEasy has engaged CFN Media to conduct a 3-month investor and market visibility program to begin on April 01, 2018.

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to attract high-quality investors to SpeakEasy while elevating the company’s financial brand.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading agency and financial media network dedicated to the worldwide cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Private and public marijuana companies in the US and Canada rely on CFN Media to succeed in the capital markets.

About SpeakEasy

SpeakEasy is a late stage ACMPR applicant that is leveraging three generations of farming experience and the largest land package of LP in Canada with 290 acres of the best agricultural land in British Columbia’s Southern interior region; known as the Napa Valley of weed country. SpeakEasy is disrupting the cultivation model by aggregating British Columbia’s best craft growers under one umbrella to produce the highest quality cannabis targeted at the highly sought after millennial recreational market.

SpeakEasy has submitted its extensive evidence package to Health Canada for its current 10,000 square feet facility and has commenced construction on its 80,000 square feet expansion facility. This 80,000 square foot facility will include growing, extraction and genetics labs that will be capable of producing more than 10,000 kg annually.

The post SpeakEasy Cannabis Club Ltd. Engages CFN Media to Develop New Investor Audience appeared first on CannabisFN.

Lexaria Expands into Transdermal, Grows Licensing Revenue

Written by Ryan Allway on

In the quickly expanding legal cannabis industry, effective delivery of the drug is an ongoing problem. Many consumers have taken to edible products as a healthier alternative to smoking, but there are still key issues with bioavailability and taste when infusing cannabinoids. Other delivery methods have gained in popularity as well, including topical creams and lotions. In addition to improving intestinal bio-absorption by as much as five to ten times in as little as 15 minutes, new laboratory study data has shown that the DehydraTECH™ technology is just as promising when it comes to transdermal applications.

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTECH™ represents a breakthrough in cannabinoid drug delivery. Lexaria’s DehydraTECH™ is technology that promotes a molecular association between cannabinoids and certain fatty acid compounds that are known to have palatability and bio-absorption enhancing properties. This combination, in turn, results in improved cannabinoid taste, bioavailability and speed of effectiveness.

Transdermal Applications

In March, the company announced the results from its first laboratory study of DehydraTECH™ on human skin at a California-based laboratory specializing in Franz diffusion cell skin permeability testing. Researchers compared the technology with two leading skin penetration enhancers, looking for penetration time, absorption quantity, and peak amounts of CBD absorbed into and through the skin at multiple testing intervals over 48 hours.

The researchers found that DehydraTECH™ was the fastest acting for absorption into the skin and demonstrated the highest overall average quantity of CBD delivered through the skin. In fact, the technology outperformed competing products by as much as 225%. The technology also lacked any odor, even without the use of perfumes, contrary to other cannabinoid industry products that can be quite odoriferous without the use of masking perfumes.

“We have theorized for some time that our DehydraTECH™ delivery system might have positive effects on skin-based delivery complementing its already commercialized gastro-intestinal product applications,” said Lexaria President John Docherty. “The first round of testing was very encouraging and showed clear benefits with regards to speed of action and, particularly, delivery of CBD across the skin barrier for potential transdermal applications.”

Building an IP Portfolio

Lexaria has already begun to commercialize the DehydraTECH™ delivery system, as well as build up its patent portfolio. Earlier this year, the company entered into two licensing agreements for the innovative platform with a cannabis edibles maker and a Canadian cannabis chocolate manufacturer. Under these agreements, the company has licensed out its technology for the development of edible products in exchange for licensing fees and royalties.

On March 22, the company announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office providing for a “composition of matter” claims that protect the specific combination of substances which enable improved taste and bio-absorption. This adds to the company’s existing “method of use” patent that had previously been granted, further protects its delivery system, and opens the door to further commercialization.

“This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH™ technology,” said Mr. Docherty. “This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed.”

Looking Ahead

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) represents a compelling investment opportunity in the cannabis industry. By solving a key issue facing many edibles manufacturers, the company hopes to license its technology to a growing number of companies in exchange for licensing fees and royalties. These high-margin revenues could unlock significant value for shareholders over the long-term.
For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Lexaria Expands into Transdermal, Grows Licensing Revenue appeared first on CannabisFN.

New MOU Underscores Benefits of RavenQuest BioMed’s Four Pillar Approach

Written by Ryan Allway on

The Canadian cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis nationwide. With a growing number of licensed producers in the space, competition is intensifying across the industry to scale up production. Investors may want to focus on companies that have taken a differentiated approach to delivering long-term shareholder value.

RavenQuest BioMed Inc. (CSE: RQB) has developed a synergistic four-pillar approach to the cannabis industry that sets it apart from other licensed producers. With a focus on Indigenous People’s partnerships, investments in near-term cultivation, immediate revenue from management services, and ongoing research and development, investors may want to take a closer look at the company following its recent partnership with an Indigenous group.

Indigenous Populations

RavenQuest BioMed has developed an indigenous-centered, end-to-end solution for cannabis production and sale on sovereign land. As part of these programs, the company provides sovereign nations with the technical know-how, staff resources, and financing opportunities in exchange for a percentage ownership in the facilities. These partnerships could lead to a steady stream of positive announcements of new production licenses over the coming quarters.

Under the guidance of Bill Robinson, the company has already identified and engaged with an impressive list of prospective Indigenous Peoples partners. Mr. Robinson serves as the head of Government/Indigenous Relations and Strategic Partnerships with over 34 years of experience with the Royal Canadian Mounted Police (RCMP). During this career, he worked closely with many organizations and developed close and trusted relationships with these communities.

Management anticipates that many of these engagements will begin as simple service contracts to build facilities that evolve into partnerships with equity interests. In other words, the services division is expected to generate deal flow for the investment division, which helps create both near-term and long-term value for shareholders. These trends have already been realized with its recent partnership with Fort McMurray #468 First Nation.

Fort McMurray Expansion

RavenQuest BioMed recently announced a Memorandum of Understanding with Fort McMurray #468 First Nation to collaboration in the development, operation, and financing of a purpose-built facility for the production of cannabis on its land. Under the terms of the agreement, the company will receive a 30 percent ownership stake in the 24,000 sq. ft. facility, which will be rapidly expanded to a maximum of 250,000 sq. ft.

“This MOU represents a key milestone for our organization,” said RavenQuest CEO George Robinson in a recent press release. “We intend to emerge as the trusted provider of choice for Indigenous Peoples’ cannabis industry partnerships across Canada … With the right partners, we see cannabis as a tremendous opportunity for economic diversification, self-reliance, employment, and harm reduction within Indigenous communities.”

Management believes that the facility will produce 50,000 kilograms of dried cannabis per year. Through its 30 percent stake, the company would be entitled to about 15,000 kilograms per year of that production. The company’s total production, along with its existing 11,000 kilograms per year facilities, bring the total to 26,000 kilograms per year at full capacity. The deal also paves the way for future projects as a valuable proof-of-concept.

Looking Ahead

RavenQuest BioMed Inc.’s (CSE: RQB) recent deal with Fort McMurray #468 First Nation underscores the company’s ability to execute on its Indigenous Peoples’ agreements, as well as shows how the company’s four pillars work together. Investors may want to take a closer look at the stock given these developments and the potential for near-term revenue and long-term shareholder value.
For more information, visit the company’s website or download their investor presentation.

Disclaimer

The post New MOU Underscores Benefits of RavenQuest BioMed’s Four Pillar Approach appeared first on CannabisFN.

FinCanna Capital Moves Closer to Commercialization in California

Written by Ryan Allway on

The cannabis industry is rapidly growing throughout the United States, but there’s little doubt that California will see the next big ‘green rush’. With nearly 40 million residents, the country’s most populous state legalized the medical use of cannabis back in 1996 and it has become an ingrained part of the culture. Investors may want to focus their attention on companies targeting the state’s industry given the vote to legalize cannabis during last year’s election.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) has a flagship investment in Cultivation Technologies Inc. (“CTI”), which owns 6-acres in Coachella, CA that it plans to develop into a cultivation center, extraction and manufacturing facilities, a testing lab, a distribution hub, and a centralized processing center for licensed medical cannabis. In addition, the company has several others royalty agreements in place targeting various parts of the industry.

California’s Burgeoning Market

The cannabis industry is projected to exceed $50 billion by 2026, according to Cowen & Co., driven by the legalization of medical and adult-use cannabis throughout the country. Arcview Market Research believes that the state could see upwards of $2.6 billion in annual revenue by 2020, which would make it larger than Colorado’s $1.5 billion market and Florida’s $1.6 billion market, and one of the largest single legal markets in the world.

While California was the first state to establish laws in support of cannabis, legalizing the plant for licensed medical use back in 1996 the majority of cultivators and collectives have been operating under the radar. Regulators have begun sending cease-and-desist letters to unlicensed operators, including advertising companies that have continued supporting unlicensed operators. In addition to these efforts, a new amendment aims to reduce price disparities between legal and illegal operations by suspending cannabis taxes until 2020, all positive signals for FinCanna’s royalty business model.

Cultivation Technologies Operations

Cultivation Technologies announced that it is directly operating its interim medical cannabis extraction facility on January 15, 2018 and plans to directly operate its permanent facility to be built on its 6-acre site in Coachella. Upon taking control of the extraction facility, CTI gained the rights to 100% of its production capacity and accordingly, is quickly advancing towards commercialization and ramping revenue at the Facility from which FinCanna is entitled to receive 50% of the profits.

In a March update, CTI announced that it began scaling up these operations. After acquiring state temporary licenses and key accounts for contract manufacturing and distribution, the company hired an experienced sales team consisting of a sales director, two full-time sales managers, and three independent sales contractors. The company further pointed out that the state was taking action to shut down unlicensed producers which should support the market for licensed producers like CTI.

Cultivation Technologies extraction facility is capable of processing an estimated 6,000 pounds of biomass per month, which translates to about 3.7 million grams of raw oil per year. The company has the ability to add an additional extraction machine and fractional distillation and winterization equipment that would increase that figure by 3,000 pounds of biomass per month and could scale to 100,000 grams of finished product per week.

Other Opportunities in the Works

FinCanna’s flagship project may be Cultivation Technologies, but the management team has started to expand beyond this campus into other areas of the industry.

On February 6, the company entered into a royalty agreement with Green Compliance Inc., which is located in Fort Lauderdale, Florida. The state-of-the-art enterprise compliance and point-of-sale software provider helps licensed medical dispensaries and cultivators comply with both the Health Insurance Portability and Accountability Act (“HIPPA”) and State Laws by ensuring that patient data is confidential and protected from security breaches. The company has commenced sales in the US and its target market is every licensed operating dispensary and cultivator in the states which have passed laws legalizing medical cannabis – currently 29 states and Washington DC.

A couple weeks later, the company signed a binding term sheet with Gram Co Holdings LLC, a California-based cannabinoid research and refinement facility focussed on the medical cannabis industry. After leasing a facility in Oakland, the company plans to finish retrofitting the facility into a large, state-of-the-art medical cannabis extraction laboratory which is expected to be operational by the end of third quarter of this year. Gram Co plans to become a premier producer of cannabinoid concentrates as well as provider of white label services.

Both of these agreements are expected to generate positive royalty income to FinCanna, while providing diversified exposure to information technology and extraction segments of the cannabis industry.

Looking Ahead

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) represents a compelling investment opportunity in California’s cannabis industry. The company is building out its portfolio initially with its royalty investment in CTI, which plans to develop a licensed medical cannabis campus in Coachella, CA and in the interim has commenced operation of an extraction laboratory with near-term potential to generate revenue. At the same time, the company also continues to enter into additional royalty agreements as evidenced by its participation in Green Compliance Inc and Gram Co Holdings LLC, to augment and diversify its revenue streams.

Of additional note for investors is the recent passing of the “Consolidated Appropriations Act 2018” a $1.3 trillion-dollar spending bill which continues protection for the implementation of state medical marijuana programs, which is the primary focus of Fincanna’s royalty investment business, through fiscal year end Sept. 30, 2018.

For more information and to read the company’s statement regarding potential risks associated with FinCanna, its business and its shares, visit www.fincannacapital.com

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please see our disclaimer below and follow the link to view our full disclosure outlining compensation: http://www.cannabisfn.com/legal-disclaimer/

The post FinCanna Capital Moves Closer to Commercialization in California appeared first on CannabisFN.

Future Farm’s Augmented Reality Company, Nextech AR Solutions, Announces Closing of CDN$2,700,000 Private Placement in Preparation for Spin Off and CSE Listing

Written by Ryan Allway on

April 3, 2018 / TheNewswire / Vancouver, British Columbia – As previously announced, Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) will spin off its augmented reality assets into a newly formed company, Nextech AR Solutions (“Nextech”). On March 28, 2018, Nextech closed on an oversubscribed private placement of CDN$2,700,000 in preparation for its listing on the CSE and OTCBB. Nextech will issue 12,000,000 new shares to Future Farm, 10,000,000 of which shall be issued pro rata to Future Farm shareholders of record on the ex-dividend date, which shall be announced in the near future. The new shares will be automatically deposited into Future Farm’s shareholders’ brokerage accounts. Shareholders need to do nothing else to receive these shares except hold shares in Future Farm as of the ex-dividend date. The Company expects Nextech to begin trading sometime in June 2018 and it will keep its shareholders updated as to developments.

“We believe that to maximize shareholder value, spinning off this asset is in the best interest of our shareholders,” comments William Gildea, CEO of Future Farm. “Nextech occupies a valuable niche in the cannabis market, providing augmented reality-enhanced packaging as well a virtual budtender platform for dispensaries.”The augmented reality market is set to grow substantially in the near future as companies such as Apple, Google, Microsoft, and Intel are now aggressively launching software and hardware to support this dynamic and fast-growing industry.

Nextech AR Solutions sold 10,852,000 units as a non-brokered private placement basis at a price of $0.25 per Unit (the “Units”). Each Unit will consist of one (1) common share of the Issuer (each, a “Share”) and one (1) common share purchase warrant (each, a “Warrant”), with each Warrant entitling the holder thereof to purchase one additional common share (each, a “Warrant Share”) of the Issuer at a price of $0.50 per Warrant Share for a period of twenty-four (24) months from their date of issue, subject to accelerated expiry upon the occurrence of certain events set out herein. The Units were offered pursuant to exemptions from the registration and prospectus requirements of applicable securities legislation.

For further information, contact William Gildea, Director, at (888) 387-3761.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman & CEO

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land. The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com, which caters to B2B customers, is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com, which caters to both large and small agriculture green houses and controlled cultivation centers.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Source: TheNewsWire (April 3, 2018 – 8:00 AM EDT)

The post Future Farm’s Augmented Reality Company, Nextech AR Solutions, Announces Closing of CDN$2,700,000 Private Placement in Preparation for Spin Off and CSE Listing appeared first on CannabisFN.

Friday Night Inc.’s Canna Hemp Launches CBD Action Sports Recovery Cream in Collaboration with Grizzly Griptape and Founder Torey Pudwill

Written by Ryan Allway on

VANCOUVER, April 3, 2018 /PRNewswire/ – Friday Night Inc. (the Company or Friday Night) (CSE: TGIF) (FWB: 1QF) (OTCQB: TGIFF) is pleased to announce a one-year licensing agreement and partnership between the Company’s subsidiary, Infused Mfg and Grizzly Griptape, LLC.

Canna Hemp’s newest product offering, “Canna Hemp X”, includes a CBD-infused recovery cream which targets the rapidly growing recovery market and launches Canna Hemp into a whole new untapped vertical in the action sports world.

Friday Night is one of the first cannabis companies to partner with a major action sports company to launch a CBD recovery product and marks the Company’s first collaboration with a well-known professional athlete.

Canna Hemps’ high-grade CBD-infused Recovery Cream has been developed to assist in the treatment and prevention of sports related injuries and chronic pain. The Recovery Cream will be available for pre-order on April 20th to coincide with industry celebrations and will be sold online and through retail outlets across the United States.

Torey Pudwill, one of the world’s top professional skateboarders and industry entrepreneur, originated Grizzly, a leading griptape company in skateboarding, featuring technical outdoor athletic apparel and accessories. Mr. Pudwill earned a spot in many podiums in a variety of competitions including Street League Skateboarding and represents well-known brands such as Red Bull^®, Diamond Supply and Footwear Co, Young Money, Plan-B Skateboards, Grizzly Grip, and many others.

“I am honored to be put in the unique position of partnering Grizzly Griptape with the leading CBD brand, Canna Hemp, to bring this amazing recovery product to the action sports industry”, remarked Mr. Pudwill, Founder of Grizzly Griptape.

“We are excited to launch our new action sports Recovery Cream in collaboration with Grizzly Griptape”, commented Mr. Brayden Sutton, President and CEO of Friday Night. He added, “Torey Pudwill is a legendary name in skateboarding and it has been a pleasure to work with him and the team at Grizzly. Our Company continues to innovate and advance our hemp and CBD-infused product line and we will continue to seek opportunities to enter into new markets.”

About Friday Night Inc.

Friday Night Inc. is a Canadian public company, which owns and controls cannabis and hemp-based assets in Las Vegas Nevada as well as an international cannabis and mining security logistics consulting firm. The Company owns 91% of Alternative Medicine Association, LC (AMA), a licensed medical and adult-use cannabis cultivation and production facility that produces its own line of unique cannabis-based products and manufactures other third-party brands. Infused MFG, also a 91% owned subsidiary, produces hemp-based, CBD products, thoughtfully crafted of high quality organic botanical ingredients. The Company’s wholly-owned subsidiary, Spire Secure Logistics is a leading provider of customized security programs, compliance, information technology, buildout design, and due diligence services for the legal cannabis, mining and investment sectors. Friday Night Inc. is focused on strengthening and expanding its current operations.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. Friday Night undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE Friday Night Inc.

Source: PR Newswire (April 3, 2018 – 8:30 AM EDT)

The post Friday Night Inc.’s Canna Hemp Launches CBD Action Sports Recovery Cream in Collaboration with Grizzly Griptape and Founder Torey Pudwill appeared first on CannabisFN.

MedMen: Strategically Building a Leading Cannabis Brand

Written by Ryan Allway on

The cannabis industry is projected to exceed $50 billion in the United States and C$22.6 billion in Canada over the coming years, according to Cowen & Co. and Deloitte analysts, driven by the legalization of medical and adult-use cannabis in a growing number of states. There are only a handful of companies that have already proven their ability to execute on this opportunity and grow.

MedMen Enterprises Inc. is the leading cannabis brand in the United States with a focus on emerging markets like California, Nevada, and New York. With a strategic focus on states with regulatory restrictions in place, the company has built a national brand capable of generating high-margin revenue across medical and adult-use markets. A recent deal with Cronos Group (NASDAQ: CRON), the NASDAQ’s first cannabis pure play company, highlights MedMen’s intentions to expand into the Canadian market with its class-defining retail experience.

MedMen LA MedMen’s store in downtown Los Angeles.

In this article, we will take a closer look at this unique strategy, management’s successful execution of the strategy, and why investors may want to take note.

Not All States Are Created Equal

The U.S. cannabis industry is projected to exceed $50 billion by 2026, according to Cowen & Co., driven by the legalization of medical and adult-use cannabis across a growing number of states. In fact, more than 90 percent of the country has legalized some form of cannabis, ranging from CBD-only medical to full recreational usage. While many states have adopted the same stance on the drug, not all markets are equal when it comes to investors.

Colorado, Washington, and Oregon were the first three states to legalize adult-use cannabis and they’ve taken a laissez-faire approach to the market. While cannabis businesses must be licensed, there aren’t explicit limits when it comes to how many can exist in the state. Other states have taken a regulated oligopoly approach to the market by limiting the total number of licenses, including California, New York, Nevada, Florida, and Ohio.

These regulated oligopolies create an opportunity to build businesses that have a regulatory barrier to entry. In addition to limiting competition, the licensing limits could translate to higher margins given the finite supply into the market. MedMen Enterprises is focused squarely on these markets where the company can build a durable advantage and maintain higher margins and revenue growth than more competitive states.

MedMen is Building an Empire

MedMen Enterprises began with the simple vision of creating cannabis consumer products. While the idea is simple, the focus on the consumer rather than the process changes how marijuana is cultivated, produced, and marketed. The company sought to build a business with unparalleled quality standards, industry-leading best practices, and a strong brand reputation. In other words, they wanted to become the envy of the cannabis industry.

Since then, the company has become the single most dominant cannabis enterprise in the legal cannabis industry. The experienced management team has broken into top consumer markets with a robust operational track record spanning the entire supply chain. The company has maintained full ownership over its licensed assets along the way while accumulating a comprehensive real estate portfolio under its stores – similar to retailers like Target.

The company’s operations can be divided into three segments:

Cultivation: The company has cultivation facilities in California, Nevada and New York. These facilities and others in the pipeline could generate more than 50,000 kilograms per year at attractive margins.
Production: The company has production and extraction space that could yield about 6,000 kilograms per year of extract. These facilities also adhere to strict food-grade standards to ensure the highest quality.
Retail: The company has 12 branded stores in California, New York and Nevada, with plans for additional outlets across the U.S. and Canada. It’s early mover advantage in sub-markets, like Los Angeles, Las Vegas, and New York City has also provided it with prime real estate locations.

MedMen SunValleyPlants One of MedMen’s cultivation facilities.

Significant Long-term Potential

Companies operating in highly competitive markets could see declining margins and higher capex as they seek to expand operations. On the other hand, those operating in regulated oligopolies could see strong revenue growth as states ramp up the legal market and ultimately expand patient and consumer access to cannabis.

MedMen Enterprises is a premier opportunity to capitalize on the latter markets with a remarkable management team and strong operational history in place. In addition, the company has numerous upcoming catalysts as it builds out its cultivation, production, and retail capacity to meet growing demand in these states.

The recently-announced partnership with Cronos Group further extends MedMen’s reach and potential. Licensed producers in Canada, like the Cronos Group, have been scrambling to secure retail assets ahead of the country’s pending full legalization of cannabis for adult use. All of these producers have been operating in the medical cannabis world, and the new retail environment demands a radically different approach in terms of marketing, products, and locations. The joint venture, called MedMen Canada, brings the best of two industry giants together to launch MedMen’s proven retail experience across Canada.

Looking Ahead

MedMen Enterprises is a unique player in the burgeoning cannabis industry. In a market characterized by letters of intent and holding companies, MedMen offers a tangible business and a strong brand with a growing presence across the supply chain.

For more information, visit the company’s website at www.medmen.com.

The post MedMen: Strategically Building a Leading Cannabis Brand appeared first on CannabisFN.

SinglePoint (SING) Wholly Owned Subsidiary SingleSeed Launches New Consumer-Facing Website Driving Sales of CBD-Based Products Nationally

Written by Ryan Allway on

SEATTLE, April 03, 2018 (GLOBE NEWSWIRE) — SinglePoint Inc. (SING) announces the official launch of the freshly revamped SingleSeed.com website, focused on selling cannabidiol (CBD) based products direct to consumer. A subsidiary of SinglePoint, SingleSeed has been actively operating in the cannabis space since 2014. Interest in CBD has increased tremendously over the years, and the CBD market is projected to hit $2.1 Billion by 2020, according to Forbes. SingleSeed is looking to capitalize in the space by creating and distributing hemp-based CBD products.

SingleSeed.com is now live and taking orders. Consumers can visit SingleSeed.com and use promo code SING on orders of $50 or more to receive a complimentary two-pack of the company’s hemp-based CBD capsules. The company is sourcing all of its CBD from U.S.-based hemp farms, all of which provide analysis of the product to ensure purity. SingleSeed is looking to position itself as the trusted, quality leader in the CBD market.

CBD products do not have any psychotropic effects and typically are used for medical purposes. Brightfield’s data estimates that hemp CBD sales have already hit $170 million in 2016 and at a 55 percent compound annual growth rate. A major benefit of hemp-based products is they can be sold globally, and with the power of e-commerce, SingleSeed will be making a major push to drive website traffic and convert sales.

The company is relying on the team’s history and expertise in payment and technology development to capitalize on the growing demand in the CBD market. SingleSeed has also engaged e-commerce experts to help drive online awareness and will also be working with online influencers to drive brand awareness.

Connect with SingleSeed.com on Facebook and Twitter to follow along and receive updates to the latest CBD trends.

About SinglePoint, Inc.
SinglePoint, Inc (SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The company portfolio includes mobile payments, ancillary cannabis services and blockchain solutions. Through acquisitions into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

Connect on social media at:
Facebook: https://www.facebook.com/SinglePointMobile
Twitter: https://twitter.com/_SinglePoint_
LinkedIn: https://www.linkedin.com/company/singlepoint
YouTube: https://www.youtube.com/user/SinglePointMobile

Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

The post SinglePoint (SING) Wholly Owned Subsidiary SingleSeed Launches New Consumer-Facing Website Driving Sales of CBD-Based Products Nationally appeared first on CannabisFN.

RavenQuest Signs MOU to Acquire Western AgriPharma Limited

Written by Ryan Allway on

Vancouver, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB)(OTCQB:RVVQF)(Frankfurt:1IT) is pleased to announce that it has signed a Memorandum of Understanding with Western AgriPharma Limited (“WAL”) pursuant to the acquisition of 100% of WAL’s outstanding shares.

Western AgriPharma Limited is a late stage applicant with Health Canada in the development of a 125,000 square foot facility, purpose-built for the production of cannabis in Port Mellon, on British Columbia’s Sunshine Coast.

“The Western AgriPharma facility would be RavenQuest’s first 100% owned, purpose-built, large scale facility to incorporate our entire suite of proprietary grow technologies,” said George Robinson, CEO of RavenQuest. “Using our proprietary grow methodologies, 125,000 square feet is more like two or three times that footprint, when you factor in what our Orbital Gardening can produce in grams-per-square-foot,” he continued. “This MOU is the culmination of what began as a simple services contract which has evolved into a potentially transformative addition to our expanding portfolio of licensed facilities. It truly illustrates the power of our services division to generate deal flow for our investment division. We believe we can continue to execute on this strategy, moving forward.”

“BC’s Sunshine Coast is located a short ferry ride away from Greater Vancouver, one of Canada’s largest cannabis markets, with over 2.5 million residents,” said Robinson. “With our significant presence in the Alberta and Ontario markets, adding a British Columbia facility is a perfect complement and a natural strategic fit,” he continued.

Kevin Smith, President & CEO of WAL, commented on the MOU, stating “RavenQuest has been a class-A partner from the start of our relationship. We have always had tremendous confidence in RavenQuest’s industry-leading expertise. That confidence has grown even more over time. We are very excited about the prospect of joining of a truly unique, top-tier cannabis company with unlimited potential.”

Completion of any transaction with WAL is subject to a number of conditions, including, but not limited to, completion of due diligence, negotiation of definitive agreements in respect of such a transaction, and the receipt of any required regulatory approvals. A transaction cannot be completed until these conditions are satisfied, and there can be no assurance that such a transaction will be completed at all. Readers are cautioned that the memorandum of understanding entered into with WAL does not set forth the terms of a potential transaction nor have such terms been negotiated or finalized.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications – 604-484-1230
Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including statements with respect to the development of a licensed cannabis production facility and anticipated production from such a facility. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Source: GlobeNewswire (April 3, 2018 – 4:00 AM EDT)

The post RavenQuest Signs MOU to Acquire Western AgriPharma Limited appeared first on CannabisFN.

Crop Infrastructure Corp. Engages CFN Media to Build Investor Audience

Written by Ryan Allway on Apr 02, 2018

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that Crop Infrastructure Corp. (CSE: CROP) (CNSX: CROP) (CROP.CN) has engaged CFN Media to conduct a 3-month investor and market visibility program to begin on April 3, 2018.

“After going public in early-March, the company is gearing up to execute on its multi-state mega greenhouse project rollout”, said Frank Lane, President of CFN Media. “The company offers US cannabis producers and processors leasing programs to access the most capital-intensive aspects of their operations: land, equipment, branding and facilities. CROP also allows investors to gain exposure to the US cannabis industry without the risk of actually touching the plant.”

Michael Yorke, CEO of Crop Infrastructure Corp., stated, “We are extremely pleased to be engaged with a credible news agency who will enable us to showcase our business model. The end of cannabis prohibition is one of the greatest opportunities of our generation and CROP has the legal framework to protect investors while profiting from this rapidly growing industry.”

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to attract high-quality investors to Crop Infrastructure Corp. while elevating the company’s financial brand.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

About Crop Infrastructure Corp.

Crop Infrastructure is engaged in the business of investing, constructing, owning and leasing mega greenhouse projects to provide turn-key real estate solutions for lease to licensed cannabis producers and processors who have best in class ethical and operational procedures. The Company’s first project and its core asset is its greenhouse project currently being constructed in Moses Lake, Washington.

Disclaimer

The post Crop Infrastructure Corp. Engages CFN Media to Build Investor Audience appeared first on CannabisFN.

Helix TCS, Inc. Announces Record Revenues for 2017

Written by Ryan Allway on

GREENWOOD VILLAGE, CO , April 02, 2018 (GLOBE NEWSWIRE) — Helix TCS, Inc. (HLIX), the leading provider of integrated operating environment solutions for the legal cannabis industry, announced its 2017 financial results today.

For the fiscal year ending December 31, 2017, Helix generated revenues of $4,029,800, representing 90% growth over 2016 revenues of $2,121,600. Gross profit increased from $286,444 in 2016 to $1,152,776 in 2017, representing an increase in gross margin from 13.5% to 28.6%, respectively.

“In 2017, our second full year of operations, Helix continued to deliver on our strategic plan. Our revenue growth is greater than the industry’s expansion rate, reflecting the reality of our significant and growing market share. Further, nearly doubling our revenue while more than doubling our gross margin is a clear indication of the quality of our operators and the robust nature of our business model.” stated Helix CEO, Zachary L. Venegas. “Driving organic growth as well as completing the acquisition and integration of Security Grade Protective Services last year demonstrates that we have the internal capabilities to execute our strategy and continue to build real value for clients, employees, and shareholders.” Our ability to offer an integrated operating solution to our clients will only continue to increase as we add services and expand into new states and countries in 2018.”

Helix’s CFO, Scott Ogur, CFA added, “We closed the Security Grade acquisition in early June and worked diligently on the seamless integration of its operations into the existing Helix security platform, which added significantly to Helix’s revenue growth and gross margin expansion.”

About Helix TCS

Helix TCS, Inc. (HLIX) is a premier provider of integrated operating environment solutions for the legal cannabis industry. Helix provides a proprietary software suite and partnership platform to the legal cannabis industry, helping clients manage inventory and supply costs and bespoke monitoring and transport solutions. Helix provides clients in the legal cannabis industry high standard security operations, including transportation, armed and unarmed guarding, training, investigation, and special services.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: our ability to fund our operations and pay any outstanding debt; fluctuations in our financial results; general economic risks; the volatile nature of the market for our products and services and other factors that could impact our anticipated growth; our ability to manage our growth; changes in laws and regulations regarding the cannabis industry and service providers in the cannabis industry; reliance on key personnel; our ability to compete effectively; security and other risks associated with our business; intellectual property risks; and other risk factors set forth from time to time in our SEC filings. Helix TCS assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

The post Helix TCS, Inc. Announces Record Revenues for 2017 appeared first on CannabisFN.

Health Canada grants Cannabis Cultivation Licence to BlissCo

Written by Ryan Allway on

BlissCo Cannabis Corp. (CSE: BLIS) (“BlissCo” or the “Company”) is pleased to announce that the Company’s wholly-owned subsidiary, Bliss Co Holdings Ltd. (“BlissCo”) has been granted a licence by Health Canada to cultivate cannabis plants and prepare dried cannabis.

“Earning our ACMPR Licence to cultivate cannabis plants from Health Canada represents a significant milestone that the Company has been working towards for four and a half years,” said the Company’s Chief Executive Officer and Chair, Damian Kettlewell.

“Our ACMPR licence to cultivate allows us to execute on our strategic plan to build a distribution, brand and extraction focused cannabis company. We can now apply to expand our license to include cannabis oil production. At the appropriate time we will apply for a license to sell both dried cannabis and cannabis oil, from our own production and with premium dried cannabis sourced from our supply agreement. Considering our two-year supply agreement with The Supreme Cannabis Company Inc., (TSX.V: FIRE) for 3,000 kilograms of premium cannabis through June 2020, BlissCo is well positioned to generate revenue, subject to earning a license to sell.

We are grateful for the diligent and mindful work of our regulator and the steadfast support of our many industry partners and shareholders. BlissCo is excited to build an iconic Canadian cannabis brand from our base in Vancouver, B.C.”

About BlissCo

BlissCo earned its Access to Cannabis for Medical Purposes Regulation ACMPR License to Cultivate on Thursday, March 29, 2018. BlissCo’s ACMPR facility in Langley, B.C. is designed to be a high-volume packager, processor and distributor of medical cannabis and adult use cannabis when it is legal in Canada, which is currently anticipated to be by August 2018at the earliest. BlissCo has a two year supply agreement with The Supreme Cannabis Company Inc. to purchase premium dried cannabis curated over the last two years from imported cannabis seeds.

BlissCo’s will apply to expand its license to cannabis oil production in Q2 2018 and will apply for its cannabis sales license at the earliest appropriate time. BlissCo will focus on high volume sales opportunities in the regulated medical use and adult use cannabis market.

The post Health Canada grants Cannabis Cultivation Licence to BlissCo appeared first on CannabisFN.

Emerald Health Therapeutics Reports 2017 Financial Results and Provides Corporate Update

Written by Ryan Allway on

VICTORIA, British Columbia, April 02, 2018 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald” or “the Company”) has filed its audited financial statements and management discussion and analysis for the fiscal year ended December 31, 2017. They are available for viewing on www.sedar.com or on the Company’s website. All figures are expressed in Canadian dollars unless otherwise stated.

“Following the Canadian federal government’s introduction in April 2017 of legislation to broadly legalize adult-use cannabis, Emerald put in motion multiple strategic steps focused on placing the company in the top tier of Canadian licensed producers and pursuing international opportunities,” said Chris Wagner, CEO of Emerald Health Therapeutics. “The company made important leadership hires; took steps to assure significant, secure supply of cannabis via large-capacity production facilities; struck multiple strategic collaborations and investments; leveraged its extensive life science industry expertise to initiate product innovation and intellectual property formation; and added substantially to its treasury.

“We look forward to a transformational year in 2018 with the expected initiation of broad legalized adult-use and our vaulting into the top tier of production capacity, enhanced branding, sophisticated sales and marketing, and progression of our medical product development and patenting plans. We are executing well on the projects we have announced and are assessing an array of potentially impactful new business opportunities.”

Selected Annual Information

The financial information presented for the years below was derived from financial statements prepared in accordance with IFRS.


	For the years ended December 31
	2017 ($)		2016 ($)		2015 ($)
Total revenue	937,654		253,321		31,291
Net loss attributable to the Company	(8,731,832	)	(2,940,501	)	(3,497,271	)
Net loss per share (basic and diluted)	(0.10	)	(0.05	)	(0.08	)
Total assets	73,730,839		4,176,329		771,679

Summary of Quarterly Results

The financial information in the following tables summarizes select financial information for the Company for the last eight quarters. This information was derived from annual financial statements prepared in accordance with IFRS or interim financial statements prepared in accordance with IFRS applicable to the preparation of interim financial statements, IAS 34, Interim Financial Reporting:


			2017
	December 31 ($)		September 30 ($)		June 30 ($)		March 31 ($)
Revenue	279,362		211,316		245,708		201,268
Expenses	2,742,508		1,661,700		1,602,443		1,205,940
Share-based payments	1,979,553		271,968		369,788		201,186
Interest income	43,024		60,997		57,497		–
Share of loss from joint venture	(44,562	)	(278,016	)	–		–
Net loss	(4,027,569	)	(1,939,371	)	(1,669,026	)	(1,205,858	)
Net loss per share (basic and diluted)	(0.04	)	(0.02	)	(0.02	)	(0.02	)


			2016
	December 31 ($)		September 30 ($)		June 30 ($)		March 31 ($)
Revenue	124,251		48,933		38,729		41,408
Expenses	867,562		590,896		547,447		507,129
Share-based payments	137,113		467,878		37,618		38,179
Net loss	(880,424	)	(1,009,841	)	(546,336	)	(503,900	)
Net loss per share (basic and diluted)	(0.01	)	(0.02	)	(0.01	)	(0.01	)

BUSINESS UPDATE FOR AND SUBSEQUENT TO THE REPORTING PERIOD

Expansion of Management Team

The Company appointed Chris Wagner as Chief Executive Officer, Rob Hill as Chief Financial Officer, and Paul Dillman as Vice President Sales & Marketing. Mr. Wagner spent more than 25 years in marketing pharmaceutical products and building biotechnology companies, including 10 years with Eli Lily. Mr. Hill brings over 20 years of accounting, finance, and senior leadership experience as a seasoned manager of private and publicly traded technology and financial services businesses in Canada, USA and Asia. Mr. Dillman brings three decades of experience in global consumer product marketing, sales, and general management. He has held senior leadership positions at The Coca-Cola Company, AB InBev, Philip Morris, and Kraft Foods.

New Site Licenses Granted by Health Canada

Health Canada issued a Cultivation Licence for Emerald’s co-owned Delta 3 greenhouse site. This optimally-designed 1.1 million ft² cannabis growing facility is located in one of the best growing climates in Canada, in Delta, BC, and is conservatively projected to produce 75,000 kg of quality cannabis annually at full production. Following receipt of the cultivation license, starter plants were transferred to the greenhouse to initiate the ACMPR sales license application process.

Health Canada also granted a sales license for a second site of the Company’s wholly owned subsidiary, Emerald Health Therapeutics Canada Inc. in Victoria, BC.

Expansion Projects

Conversion of the first 250,000 ft² section of the Delta 3 greenhouse to cannabis production is substantially complete, with conversion of the remainder of the 1.1 million ft² greenhouse ongoing and on schedule. Senior growing, financial, human resources and operational personnel, including the established team transferred from Village Farms, are in place for production ramp-up. Pure Sunfarms is pursuing a strategy to potentially accelerate production using short-term rental generation equipment. This would provide incremental electricity to power supplemental lighting during the 2018/2019 winter months when there is insufficient natural sunlight available and prior to the installation of the approved additional 24MW from the local utility. Successful execution of this plan is expected to increase Pure Sunfarms’ production in 2019 by up to 30% over the current target of approximately 35,000 to 40,000 kilograms of dried cannabis.

Apart from making tremendous progress on the joint venture Delta 3 greenhouse conversion project, the Company has completed a significant amount of construction at its Metro Vancouver site and in October 2017 applied to Health Canada to produce cannabis at this facility.

DMG Blockchain Solutions Joint Venture

Emerald and DMG Blockchain signed a letter of intent to form a joint venture, to be named CannaChain Technologies, to develop a blockchain-based supply chain management system and e-commerce marketplace for the legal cannabis industry.

Namaste Technologies Collaboration

The Company and Namaste signed a non-binding letter of intent to collaborate on strategic business opportunities worldwide and develop a fully integrated e-commerce platform to serve as a retail channel for the Company’s patients.

Acquisition of Northern Vine

The Company acquired control of Northern Vine, a Licensed Dealer under the provisions of the Controlled Drugs and Substances Act (Canada), which permits Northern Vine to carry out a broader range of cannabis research and development and pursue international business opportunities.

TSX Venture 50 Performer

The Company achieved the #1 ranking in the TSX Venture 50 for the clean technology & life science sector in 2017 and was recognized as a top performing company for the second consecutive year. The TSX Venture 50 is the TSX Venture Exchange’s annual ranking of Canada’s top 50 emerging publicly traded companies.

Capital Resources

Subsequent to year end, the Company raised additional gross proceeds of $54.9 million from private placement offerings and warrant exercises, bringing total gross proceeds raised since February 2017 from unit issuances and warrant exercises to $123.8 million.

The Company had approximately $89 million in cash and cash equivalents as at March 29, 2018.

As of March 29, 2018, the Company had 121.5 million common shares outstanding and 139.7 million common shares outstanding on a fully diluted basis, after giving effect to outstanding options, warrants, and restricted stock units.

Financial Reports

Full details of the financial reports and operating results for the fiscal year 2017 are described in the Company’s consolidated financial statements with accompanying notes and related Management’s Discussion and Analysis. These documents and additional information on Emerald are available on SEDAR at www.sedar.com.

About Emerald Health Therapeutics

Emerald Health Therapeutics (TSXV:EMH) (OTCQX:EMHTF) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. It is adding a 500,000 ft² greenhouse in Metro Vancouver to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a joint venture with Village Farms International, Inc. that is converting an existing 1.1 million ft² greenhouse in Delta, BC to grow cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. The company is part of the Emerald Health Group, with multiple companies focused on developing the cannabis and cannabinoid products with potential wellness and medical benefits.

Please visit www.emeraldhealth.ca for more information or contact:

Rob Hill
CFO
(800) 757 3536 Ext. #5

Ray Lagace
Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. As a result, we cannot guarantee that any forward-looking statement will materialize and readers are cautioned not to place undue reliance on these forward looking statements. For more exhaustive information on these risks and uncertainties, the reader should refer to the risk factors described in the management’s discussion and analysis for the year ended December 31, 2017. The forward-looking statements contained in this press release represent our expectations as of the date hereof. We disclaim any intention and assume no obligation to update or revise any forward-looking statements. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

Source: GlobeNewswire (April 2, 2018 – 8:00 AM EDT)

The post Emerald Health Therapeutics Reports 2017 Financial Results and Provides Corporate Update appeared first on CannabisFN.

CFN Media Exclusive Interviews with BioTrackTHC

Written by Ryan Allway on

In the legal cannabis industry, accurate and efficient tracking of the plant from seed-to-sale is critical in order to provide a safe and consistent product to consumers. BioTrackTHC is a global leader in canna-business software solutions, offering all-in-one tracking from cultivation to dispensary POS. The company operates in 28 states and 5 countries, and has options for both businesses and governments in order to help make implementation of cannabis regulations as smooth as possible.

The company recently agreed to merge with Helix TCS (OTCQB: HLIX), giving investors exposure to the industry-leading platform for the first time. Both businesses will continue to operate independently while offering complementary services. What follows are two interviews with BioTrackTHC officers conducted just before the merger.

The first is a video interview with CEO Patrick Vo.

CFN Media also recently spoke with BioTrackTHC Chief Operating Officer Dr. Moe Afaneh about the company’s innovative technology and their multitude of software programs designed to ensure safety and transparency.

CFN: What is the history of BioTrack?

Dr. Moe Afaneh: The company got its start back in the late 2000’s; we initially developed a software solution to track prescription opioids using a biometric screening method. At the time, I was working as a pharmacist and the company brought me on to help inform the processes around tracking prescription opioids and to help develop that solution. Then, around 2009, licensed cannabis operators from Colorado approached the company and asked if we had any interest in repurposing the software to track cannabis. That spurred the company to pivot and develop BioTrackTHC, which was developed independently of the opioid tracking solution.

There are some similarities in the principles of tracking any given product, but for the most part, tracking cannabis is completely unique from tracking prescription opioids. We worked directly with licensed operators at every stage of the cannabis supply-chain to understand the necessities of tracking the plant from seed-to-sale to ensure that we were meeting the exact needs of the licensees. It’s now part of our regular processes to seek out that feedback from our users and licensees to understand how to optimize future improvements of the cannabis software solution.

Today, we offer full-vertical commercial tracking solutions for licensed operators in every state with a running program. We also provide government traceability systems for regulators and agencies alike. We’re the only company in the history of cannabis to provide commercial and government solutions for both medical and recreational cannabis, as well as maintain a private-sector, self-regulated traceability system to sustain a state’s industry (Washington). We’ve seen seed-to-sale from literally every possible angle in the industry and because of that, nobody knows it better.

CFN: What sets you apart from other seed-to-sale tracking solutions?

MA: There’s nothing more valuable than having an experienced partner in this industry. Every single state has completely unique rules and regulations surrounding their cannabis programs and those rules are constantly developing and changing as states figure out the ideal structure for their respective markets. Figuring out how to adhere to all of the rules and regulations while staying atop the ever-changing landscape, let alone in multiple states at a time, requires an experienced partner to help you establish sound processes and workflows, as well as a highly flexible tracking solution that can adapt to your ever-changing needs.

We’ve helped implement compliant workflows for every stage of a licensed cannabis business – cultivation, processing, transport/distribution, retail sale – in 28 states and 5 countries, each of which have a completely unique set of rules and regulations. No matter what type of regulatory landscape you’re faced with, we’ve helped implement compliant businesses in a similar environment. Additionally, we offer the most customizable software solution in cannabis. As your business’s needs change, or your rules and regulations develop, your system can adapt with ease.

CFN: What markets are you currently in and what are your goals for expansion?

MA: Currently, BioTrack operates in over 2,200 locations across 28 states and 5 countries, as well as D.C. and Puerto Rico. Our focus is currently on the US market and ensuring that we’re a viable cannabis software and cannabis POS option for businesses in every state with a live program. As our company continues to grow, we’ve shifted our focus heavily towards our commercial product and will allocate the majority of our resources to ensuring we’re competitive in all commercial markets, especially the burgeoning California market.

In addition to growing our commercial product offering, we’re excited to be adding two more state contracts to our portfolio in early 2018 with the additions of North Dakota and Arkansas, as well as vetting potential opportunities that make sense for BioTrack, as they arise. We’re looking forward to the rapid development in markets like New Jersey, Michigan, Ohio, and hopefully many more! We’re also optimistic about international opportunities that make sense for us.

CFN: What are your main objectives in the cannabis industry overall?

MA: As providers of seed-to-sale technology, our goal as a company is to prove that this industry can operate safely through transparency and accountability. As a young, adult-oriented industry, there are a lot of opponents of what we’re trying to do, and their chief concern is making sure cannabis stays out of the wrong hands. We want to bring those people into our world and help them to understand that keeping cannabis out of the wrong hands and enforcing accountability, and ultimately promoting safety, is exactly what we’re here to do. We want to prove to the doubters and to the believers that companies like ours enable this industry to happen the right way.

Our other goal is to see this industry succeed as a whole. Cannabis draws all kinds of reactions from supporters and opponents, but this industry is continuing to grow whether you’re for it or against it. So no matter where you stand on the issue, one thing we can all get behind is doing it in a manner that is transparent, accountable, and promotes public safety, which is what BioTrack exists to do. Our goal is to bring cannabis out of prohibition by proving that it can be produced and sold safely and responsibly.

Disclaimer

The post CFN Media Exclusive Interviews with BioTrackTHC appeared first on CannabisFN.

Friday Night Inc. Announces Second Quarter Financial Results

Written by Ryan Allway on Mar 30, 2018

VANCOUVER, March 29, 2018 /PRNewswire/ – Friday Night Inc. (the Company or Friday Night) (CSE: TGIF) (FWB: 1QF) (OTCQB: TGIFF) is pleased to announce financial results for the second quarter ending January 31, 2018.

Friday Night Inc. (CNW Group/Friday Night Inc.)

The Company announced a strong quarterly report with sales increases from both subsidiaries in Las Vegas, Nevada. Alternative Medicine Association (“AMA”) has increased its focus on producing higher quality plants that command a higher price in the marketplace. Infused Mfg. has increased its product offering and both its top line sales and profits significantly contributed to the Company’s bottom line. Canna Hemp products have been successfully received in Nevada and are now selling in retail locations in California and additional sales representatives have been added to expand the distribution network. With the recent acquisition of Spire Secure Logistics, management feels it has acquired a business with significant cash flow potential that will benefit from the growing cannabis sector.

Q2 Financial Highlights (Amounts in CND dollars)

Total sales increase from $2,464,487 in Q1 to $2,962,699 in Q2, which represents a 20.2% increase
US operations 6-month total sales of $5.4 million
Gross profit in Q2 of $1,579,127
Cash at end of period of $15,753,139
Infused MFG increased sales by 45%
AMA increased sales by 11%

Selected Quarterly Information

The following table shows results for the quarter ended January 31, 2018 in Canadian dollars.

	3 months ended January 31, 2018
	(unaudited)
Revenue	CDN$ 2,962,699
Gross Profit	CDN$ 1,579,127
Non-Current Assets	CDN$ 17,397,003
Cash at end of period	CDN$ 15,753,139
Total Liabilities	CDN$ 3,735,685

Developments in Q2

On November 3, 2017, the Company announced an agreement with MariMed Advisors for an exclusive licensing deal to produce MariMed THC products including their unique sublingual “Melts” product line, a THC and CBD “Mints” line, “Kalm Corn” products and the “Betty Eddies” and “Berry Bombs” line of products. Under the terms of the agreement, AMA is, on an exclusive basis, producing these and other MariMed products using their proprietary processes and distributing these products to all dispensaries in Nevada.
On November 10, 2017, Friday Night announced that AMA had executed an agreement to provide cultivation services to another Nevadalicensed facility owned by Harvest Foundation.
On December 6, 2017, the Company announced that AMA had signed a production contract to produce high-grade concentrates for a major dispensary chain in Nevada.

Subsequent Developments

The following transactions were entered subsequent to January 31, 2018:

The Company acquired as a wholly owned subsidiary, Spire Secure Logistics Inc., a Canadian private company specializing in security, intelligence, and compliance with international clients and expertise in both the regulated cannabis industry and other sectors.
The Company closed on the purchase of an additional 2.78 acres of land contiguous to its current location that will host its new cultivation facility. It now owns over 4.17 acres following the transaction on a major thoroughfare in Las Vegas. The Company plans to build a new state-of-the-art 67,000 sq. ft. cultivation facility on this land that will help further scale both revenue and product lines.
Friday Night announced on February 21st that it had terminated its letter of intent dated December 20, 2017 to acquire Body & Mind Inc. in an all-stock transaction.

Management focused and executed on several milestones surrounding its Nevada business expansion plans.

Detailed information on the financials and the management’s discussion and analysis can be found at http://sedar.com/.

About Friday Night Inc.

SOURCE Friday Night Inc.

Source: PR Newswire (March 29, 2018 – 2:58 PM EDT)

The post Friday Night Inc. Announces Second Quarter Financial Results appeared first on CannabisFN.

Emblem Signs Key Supplier Agreement with Shoppers Drug Mart

Written by Ryan Allway on Mar 29, 2018

Emblem Corp. (TSXV:EMC) (EMC.WT) (“Emblem” or the “Company”), has announced today that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart.

Subject to Health Canada’s approval of Shoppers Drug Mart’s application to be a licensed producer, under the terms of the agreement the Company will supply Shoppers Drug Mart with Emblem branded medical cannabis products. It is expected the products will be sold online, as Canadian regulations currently restrict the sale of medical cannabis in retail pharmacies.

Nick Dean, CEO of Emblem Corp., says the deal is an important milestone for Emblem. “From the very beginning we’ve been very focused on being a leader in the medical cannabis space, not only from the production side, but also when it comes to physician and patient education,” says Dean. “Today’s deal with Shoppers Drug Mart helps to solidify that and positions us well to be a world leader of cannabis for medical purposes.”

About Emblem
Emblem Corp., through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.

For further information contact:

Ali Mahdavi
Vice President, Capital Markets and Investor Relations
Emblem Corp.
416.962.3300
alimahdavi@emblemcorp.com

Forward-looking statements

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (together, “forward-looking statements”). All statements and information contained herein that is not clearly historical in nature may constitute a forward-looking statement. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company’s annual information form dated October 18, 2017 which has been filed with the Canadian Securities Administrators and is available on www.sedar.com. Any forward-looking statements contained herein are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.

The post Emblem Signs Key Supplier Agreement with Shoppers Drug Mart appeared first on CannabisFN.

MedMen Engages CFN Media

Written by Ryan Allway on

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

SEATTLE, WA — March 29, 2018 — CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that MM Enterprises USA, LLC (“MedMen Enterprises”) has engaged CFN Media.

“MedMen is one of the largest American cannabis operators with world class dispensaries and cultivation facilities in three US states and over 700 employees”, said Frank Lane, President of CFN Media. “It is an important player in the emerging cannabis market.”

“The cannabis industry continues to grow by leaps and bounds. California will add some $5 billion in sales with the start of adult-use, and Canada, without the constraint of a blanket federal prohibition, has seen the rise of a vibrant, sophisticated capital market,” said MedMen Co-founder and CEO Adam Bierman. “It is no longer about having a novel concept and a great plan. You have to have a successful track record as well. MedMen has that.”

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused audiences and media across North America to educate them about MedMen Enterprises.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

About MedMen

MedMen Enterprises is the United States’ preeminent cannabis company with assets and operations in key markets. It is one of the most recognized brands in the cannabis world today. Based in Los Angeles, MedMen employs nearly 700 workers, and is the single largest financial supporter of progressive marijuana laws. Visit http://www.medmen.com

The post MedMen Engages CFN Media appeared first on CannabisFN.

LastMile Delivery Platform Will Enable SMBs and Cannabis Delivery Businesses to Effectively Manage Deliveries; Submits to Apple and Google Play

Written by Ryan Allway on

SEATTLE, March 29, 2018 (GLOBE NEWSWIRE) — SinglePoint (SING) announces LastMile Delivery, a platform giving small businesses and cannabis delivery companies a solution to efficiently manage deliveries. This is the first app launched under SinglePoint’s joint venture with AppSwarm (SWRM). The two companies have closely worked together to define and launch a scalable service geared toward providing an agnostic platform for delivery businesses to accept orders, locate drivers and keep records of each delivery every step of the way, from initial manifest to completion of delivery product. The application is currently under review, and it is anticipated it will be approved for beta testing in app stores soon. Once official acceptance occurs, SinglePoint and AppSwarm will launch beta testing, implement feedback and launch the production service. The companies estimate production should occur within 45 to 60 days.

The current status quo in the cannabis delivery space is to simply keep hand and electronic records of delivery manifests. LastMile aims to automate this for delivery services and provide a way to simply keep track of and verify all delivery activities. Many states require these businesses to keep all delivery records, but there is not currently a standout provider to make the process efficient. SinglePoint and AppSwarm believe that LastMile will increase the efficiency of delivery services as well as sales for cannabis businesses through use of order-ahead capabilities and enabling customers to locate the service nearest to them.

LastMile Delivery will provide the tools for cannabis delivery businesses to have an Uber-like feel when it comes to their orders and deliveries. Many state laws prevent simply letting any contract driver deliver cannabis; drivers must have credentials and licenses to deliver cannabis. LastMile will provide drivers with an easy, convenient way to verify both their own credentials and the credentials of patients who are receiving deliveries, enabling businesses to use their own drivers or credentialed drivers who are licensed to pick up and deliver cannabis.

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

The post LastMile Delivery Platform Will Enable SMBs and Cannabis Delivery Businesses to Effectively Manage Deliveries; Submits to Apple and Google Play appeared first on CannabisFN.

Future Farm Prepares Belfast, Maine Hemp Propagation Facility for 200,000 Seedlings

Written by Ryan Allway on

March 29, 2018 / TheNewswire / Vancouver, British Columbia – Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce that it has begun preparations for the propagation of industrial hemp at its Belfast, Maine facility.

As previously announced, the Company entered into a lease agreement for an initial 12,960 sq. ft. of space in a 60,000 sq. ft. building in Belfast, Maine. The Company has engaged GGS Structures of Vineland Station, Ontario to outfit planting trays, which will house over 200,000 hemp seedlings for the 2018-growing season. In addition to ordering the seeding tables, Future Farm has also engaged a local electrician and contractor to begin the build-out of its propagation room, which Future Farm anticipates will be completed by May 1st. This schedule should allow sufficient time to grow the seedlings to a point where they are hardy enough to be planted outside at the Company’s Amity 120-acre and Hersey 100-acre farms before Maine’s June 1st deadline.

Senate Majority Leader Mitch McConnell said Monday that he will introduce legislation to legalize hemp as an agricultural commodity. The Republican made the announcement in his home state of Kentucky, which has been at the forefront of hemp’s comeback. McConnell says the legislation would also remove the federal barriers in place, which will help expand the domestic production of hemp. It will also give hemp researchers the chance to apply for competitive federal grants from the U.S. Department of Agriculture, allowing them to continue their work with the support of federal research dollars.

Looking forward to 2019, the Company expects to exercise its option to expand within the Belfast facility and to double production in 2019 at this location. With over 100 organic certified acres ready to plant in 2018 and an additional 1,000 acres available for expansion, Future Farm is poised to become the largest hemp farm in the North East.

“We have been working day and night to capitalize on this year’s growing season,” Derek Ross, President of Cannatech and Future Farm’s joint venture partner in Maine comments. “It’s great to see a plan come together and I’m very excited to have the opportunity to work with the local community to develop this project.”

For further information, contact William Gildea, Director, at (888) 387-3761.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman & CEO

About Future Farm

Source: TheNewsWire (March 29, 2018 – 8:00 AM EDT)

The post Future Farm Prepares Belfast, Maine Hemp Propagation Facility for 200,000 Seedlings appeared first on CannabisFN.

Why Hemp Could Become the Next Biggest Cash Crop and How to Profit

Written by Ryan Allway on Mar 28, 2018

Hemp is one of the oldest plants that has been in continuous use throughout history. In 1977, Carl Sagan went so far as to suggest that hemp could have been the world’s first agricultural crop, leading to the development of civilization as we know it. Hemp was also America’s largest cash crop for over 150 years following the Revolutionary War. In fact, the Declaration of Independence was drafted on hemp paper.

In 1957, hemp was banned in the United States due to concerns about its psychoactive cousin, marijuana. The War on Drugs began in 1986 and imposed mandatory minimum sentences and raised federal penalties for the possession and distribution of drugs. In 2001, the Hemp Industry Association and other companies took legal action against the Drug Enforcement Administration and a three year legal battle led to re-legalization of hemp. In Canada, growing Industrial hemp was re-legalized in 1998, creating an instant market for hemps foods. With imminent revised MMJ and Industrial Hemp regulations in 2018, full crop utilization of Industrial Hemp will allow companies to not only harvest Industrial Hemp for its nutritional value but begin to harvest the crop to extract Cannabidiol (CBD). This gives Canadian companies an advantage in the sector as Hemp remains illegal to grow in the United States except for research and development purposes.

Naturally Splendid Enterprises Inc. (TSX-V: NSP) (OTCQB: NSPDF) (FRK: 50N) aims to become a leading provider of plant-based functional foods and ingredients with a focus on hemp-based products. Investors interested in capitalizing on the hemp revolution may want to take a closer look at the stock given its innovative technology and growing product lines.

Hemp’s Tremendous Value

Hemp is unique in that every part of the plant can be used and it’s extremely easy to grow in every state. In fact, the growing season is so short that farmers can plant hemp after harvesting their other crops. The plants deep roots help create ideal growing conditions for future crops, while its dense foliage chokes out weeds. These attributes make it a perfect cash crop for farmers throughout the United States and around the world.

In the past, hemp was world’s standard fiber with unmatched tensile strength. After removing the fiber-bearing cortex from the rest of the stalk, hemp can be used to make any fiber-based or cellulose-based product. The fiber was used to produce over 5,000 different textile products before prohibition. With recent advances in processing, these end uses could be rapidly expanded to applications like replacing many plastics.

Hemp seeds are also very nutritious. In addition to a healthy dose of omega-3 fatty acids, the seeds are a better source of high-quality protein than chia seeds or flaxseeds. They’re also a great source of vitamin E and minerals like potassium, magnesium, calcium, iron, and zinc. In recent years, the plant has become an important source of cannabidiol (CBD) – the non-psychoactive cousin of tetrahydrocannabinol (THC).

Researchers have taken a growing interest in CBD due to its beneficial influence on the human endocannabinoid system, which is responsible for regulating a variety of physiological and cognitive processes. A growing body of research has found that CBD could help relieve pain, reduce inflammation, reduce anxiety, protect the brain, and even regulate blood sugar levels, making it a potentially valuable alternative to conventional pharmaceuticals.

Developing Consumer Products

There are many companies developing hemp-based consumer products, nutraceuticals, and pharmaceuticals. Unfortunately, many of them have experienced limited success due to issues with bioavailability and formulation. Pharmaceutical companies have found that the effects of cannabinoids are reduced by first-pass metabolism in the liver, while consumer products companies have difficulty combining CBD oil with common products.

Naturally Splendid’s HempOmega™ and encapsulation technology has the potential to solve these problems. The homogenous powder or emulsion is created from microencapsulated hemp seed oil ( or any plant-based input ) and can be combined into a wide range of existing products, such as food, beverages, supplements, pet foods, livestock feed, cosmetics, and much more. The innovative technology has been commercialized and is produced in a state of the art manufacturing facility in Canada that exceeds food, cosmetics, and drug manufacturing standards.

The company manufactures three in-house product lines, including NATERA®, CHII™, and ElevateMe™. Management launched NATERA®CBD and NATERA® Skincare last year to augment its existing product lines and bulk ingredient sales. CHII™ provides a full line of hemp food products sold online across North America, while NATERA® and ElevateMe™ has an established presence in over 1,200 retail stores, including Costco, Whole Foods, and Sobeys.

The company’s manufacturing facility is also equipped to provide co-packaging and private-labeling opportunities. As a provider of bulk ingredients, this setup means that the company can quickly formulate and manufacture private label products on behalf of larger brands, which opens up a big door to partnership opportunities. The company also has the flexibility to further develop in-house brands, such as its Pawsitive FX pet line, NATERA® and future brand extensions, plus many other new innovative brands/products currently under development.

Looking Ahead
Naturally Splendid Enterprises Inc. (TSX-V: NSP) (OTCQB: NSPDF) (FRK: 50N) is well positioned to become a leader in the burgeoning hemp industry. With its expanding capabilities in their manufacturing facility in Pitt Meadows and the addition of a Dealer’s License in 2018, the opportunity to build on revenues has never been greater.

The company generated $7.3 million in 2016 revenue mostly in exports, however saw a contraction in exports in 2017. The Company continues to strengthen its retail presence and distribution. Management aims to continue to grow revenue through an increased retail presence in North America as well as expanding opportunities in countries such as Australia where hemp regulations have recently changed and NATERA® is already in an estimated 150 retail stores.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The post Why Hemp Could Become the Next Biggest Cash Crop and How to Profit appeared first on CannabisFN.

India Globalization Capital (IGC) Launches Hyalolex for Alzheimer’s

Written by Ryan Allway on

India Globalization Capital Inc. (NYSE American: IGC) (“IGC”) recently announced that it was launching Hyalolex, its flagship cannabinoid-based combination therapy supplement for Alzheimer’s disease, in Puerto Rico. The company signed an agreement with DaMa Pharmaceutical to distribute Hyalolex in 10 of the 30 medical dispensaries in Puerto Rico. It begs the question why Puerto Rico and not one of the many states that have legalized medical marijuana?

Alzheimer’s is a devastating disease that affects more than 5.5 million Americans and over 40 million people worldwide with no cure. At a cost of over $277 billion to Medicare and Medicaid each year, it’s also widely considered to be the country’s most expensive disease.

The Latino population will grow to about 129 million by 2016, or about 31 percent of the nation’s population, making it America’s largest minority group, according to usagainstalzheimers.org. The likelihood of getting Alzheimer’s doubles about every 5 years, after 65, reaching about 50% by the age of 85. Due to several underlying factors, Latinos are about 50% more likely to develop Alzheimer’s than Caucasians. Due to the rapidly aging population in the Latino community, the cost associated with Alzheimer’s and the cost associated with caregivers is predicted to skyrocket over the coming years.

Since Puerto Rico has a large Latino population, the company has decided to launch Hyalolex in the territory before rolling it out to the wider United States. The company also plans to fine-tune its Spanish language messaging, customer care, website, marketing materials, and other supporting activities before launching into Latino markets in California, Florida, New York, and Texas (when legal). This approach is similar to that of large pharmaceutical companies. Culturally, Latinos also prefer natural non-Western medicine over traditional medicine.

IGC’s Hyalolex is a twice-or thrice-daily liquid supplement that’s designed for patients suffering from mild to advanced Alzheimer’s disease. In early studies, the medication has been shown to inhibit the formation of harmful plaques and tangles – two hallmarks of Alzheimer’s. The supplement has also been shown to enhance mitochondrial function, reduce inflammation, and modulate other Alzheimer’s symptoms like anxiety, agitation, and sleep disorder. These benefits could also reduce stress for caregivers, which is a major cost when treating the disease.

In addition to commercializing its most advanced product, the company hopes to collect data on Hyalolex’s performance within a diverse patient set for its future clinical trials. The company plans to do this by deploying a QR-code based product assurance, information dissemination, and data collection system.

Looking Ahead

India Globalization Capital Inc. (NYSE MKT: IGC) represents a unique opportunity within the multi-billion dollar Alzheimer’s disease market. The company is strategically positioned as the only cannabis based pharmaceutical company in the Alzheimer’s space. By targeting a niche market and setting up a distribution to productize its intellectual property into many of the larger markets, the company is uniquely positioned to grow long-term shareholder value. IGC has patents filed for formulations for Parkinson’s, PTSD, pain, epilepsy in cats and dogs, among others, as potential products that it can bring to market.
For more information, visit the company’s corporate website or its product website.

Disclaimer

The post India Globalization Capital (IGC) Launches Hyalolex for Alzheimer’s appeared first on CannabisFN.

Micron Waste Technologies Testifies to the Canadian Senate Regarding Innovations in Cannabis Waste Management

Written by Ryan Allway on

VANCOUVER, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) — Micron Waste Technologies Inc. (“Micron” or the “Company”) (CSE:MWM) (OTC:MICWF) (Frankfurt:7FM2), a leading Canadian innovator in organic waste management, presented details of the development of its on-site cannabis waste treatment system for licensed producers during testimony to the Standing Senate Committee on Agriculture and Forestry (AGFO) yesterday. Micron’s solution removes cannabis residues and is well positioned to disrupt the current Canadian and American cannabis waste disposal models.

The AGFO committee, which is studying the possible effects of cannabinoid residues on the environment, heard testimony from Micron’s President Alfred Wong and Aurora Cannabis Inc. Chief Corporate Officer and Micron board member Cam Battley. In January 2018, Micron and Aurora (“Aurora”) (TSX:ACB) (OTCQB:ACBFF) (Frankfurt:21P) (WKN:A1C4WM) finalized a collaboration agreement for the treatment of organic waste generated in the cultivation and production of cannabis products.

“Micron’s solution is on track to be installed at Aurora’s facility by June of this year,” Mr. Wong testified. “This on-site process will minimise the cost of shipping cannabis waste to landfill or composting facilities and will help reduce greenhouse gas emissions and carbon footprint. Our clean agricultural technology will provide licensed producers with an environmentally-sound, cost-effective solution for cannabis waste treatment and is anticipated to be able to meet the scale of Canada’s growing cannabis industry.”

The world’s first on-site cannabis disposal unit will process cannabis waste, removing traceable active cannabinoid residues such as THC and CBD, and treat the resulting effluent to meet municipal sewage bylaw standards. The first operational unit will be installed at Aurora’s 55,000 square foot cultivating facility at Cremona, Alberta.

“As one of the world’s leading cannabis companies, Aurora is demonstrating leadership in both environmental stewardship and cost management, by collaborating with Micron to optimize Micron’s innovative, proprietary digester technology for widespread use in the cannabis sector,” said Mr. Battley. “Together we’re repurposing and refining green technology already used successfully for supermarket waste disposal, to meet the growing needs of the cannabis industry.”

In 2017, the amount of cannabis produced in Canada by licensed producers was estimated at 53 metric tonnes. According to Martin Landry of GMP Securities, in 2020, cannabis supply is expected to increase to 1221 metric tons. As cannabis waste increases exponentially, the benefits of sustainable, environmentally-sound cannabis disposal systems, like the one offered by Micron, will be magnified.

Canadian Innovation in Organic Waste Disposal

The merits of Micron’s technology have been successfully proven with a grocery supermarket chain located in British Columbia, with whom Micron has entered into an Memorandum of Understanding to review additional installations. The Micron Waste solution is an aerobic digestion process that breaks down organic waste within 24-48 hours and treats the resulting effluent to meet municipal sewage bylaw standards.

On Behalf of the Board
Rav Mlait
Chief Executive Officer and Director

For further information contact:

Media Inquiries:
Karen Lauriston
+1.905.691.1185
karen@micronwaste.com

Investor Relations:
+1.844.318.8216
info@micronwaste.com
www.micronwaste.com

The Exchange does not accept responsibility for the adequacy or accuracy of this release

FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

Source: GlobeNewswire (March 28, 2018 – 8:30 AM EDT)

The post Micron Waste Technologies Testifies to the Canadian Senate Regarding Innovations in Cannabis Waste Management appeared first on CannabisFN.

Choom™ Signs Letter of Intent to Acquire Late Stage Saskatchewan ACMPR Applicant and Retail Brand

Written by Ryan Allway on

VANCOUVER, March 28, 2018 /CNW/ – Choom™ (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom”) is pleased to announce that it has signed a Letter of Intent (“LOI”) to acquire Flower Power Cannabis Pharms Inc. (“Flower Power” or the “Target”), a retail brand experience cannabis company, and its wholly-owned subsidiary High Way 10 Cannabis Pharms Inc. (“High Way 10”), another advanced-stage cannabis production license applicant under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). High Way 10 is located in southern Saskatchewan and is in the active review stage of Health Canada’s application process under the ACMPR.

Choom Holdings Inc. (CNW Group/Choom Holdings Inc.)

High Way 10’s initial 16,000 sq. ft. facility is located on a 120-acre parcel of land providing ample room for future expansion and is capable of producing approximately 1500 kg of dried cannabis per annum.

Flower Power is advancing their retail store experience strategy across the country, beginning in their home province of Saskatchewan. The company is focused on creating a consumer experience that elevates and evolves the traditional dispensary vibe and intends to have a hybrid of corporately owned and franchised dispensaries subject to the formal legalization of recreational cannabis by Health Canada and provincial and municipal guidelines. Flower Power is actively working through Saskatchewan’s retail dispensary permitting and RFP process for the lottery to secure the right to receive a license in multiple markets in the province.

Chris Bogart, President and CEO of Choom™ states, “We are very pleased Choom™ has increased its total production capacity with the addition of potentially our fourth advanced stage applicant. Upon completion of the tenant improvements within the initial 17,000 sq. ft. building, Flower Power intends to submit its affirmation of readiness (“AOR”) evidence package to Health Canada, which they hope will follow with the receipt of a cultivation license shortly thereafter. This acquisition further demonstrates our commitment to develop and acquire license and production assets along with retail dispensary opportunities, helping to position us to scale-up rapidly to meet the anticipated Canadian recreation market demand.”

Acquisition Terms

Pursuant to the LOI, the Company intends to acquire all of the shares of the Target, which will become a wholly-owned subsidiary of the Company (the “Transaction”), and the Company will issue to the Target shareholders, based on their pro rata holdings, the following shares in the capital of the Company (the “Choom Shares”):

$2,000,000 in Choom Shares on the closing date of the acquisition, calculated using the then 10-day VWAP trading price of the Choom Shares. These Choom Shares will, subject to certain exceptions, be held in escrow and released 10% on the closing and the balance in 15% increments every 6 months over a 36-month period.
$3,000,000 in Choom Shares following receipt by High Way 10 of its confirmation of readiness under the ACMPR application process and calculated using the then 10-day VWAP trading price of the Choom Shares. These Choom Shares will, subject to certain exceptions, be held in escrow and released 10% on the date of receipt of confirmation of readiness and the balance in 22.5% increments every 6 months over a 24-month period.
$3,000,000 in Choom Shares following receipt by High Way 10 of its cannabis sales license under the ACMPR, based on the then 10-day VWAP trading price of the Choom Shares. These Choom Shares will, subject to certain exceptions, be held in escrow and released 10% on the date of receipt of the cannabis sales license and the balance in 45% increments every 6 months over a 12-month period.

The definitive share purchase agreement will include customary conditions, including obtaining all necessary corporate approvals, completion of due diligence and applicable exchange acceptances. The Target acquisition is arms-length. There can be no assurance that the Transaction will be completed as proposed, or at all. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release.

“Ideas are the most powerful force in the universe and mother nature has provided us with a beautiful opportunity to create experiences and products that foster unique thinking, creativity and understanding” shares Clayton Sparks, Founder and CEO of Flower Power. “It is extremely exciting, and we are deeply honored to be welcomed into the Choom ‘family’ of companies and participate in this significant SHIFT in our society and how we experience and treat pleasure and pain.”

SAY HELLO TO CHOOM^TMChoom™ was created for and inspired by the Choom Gang; a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom“. Now, after four decades, Choom™ is bringing the spirit of Hawaii to Canada. We’re planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb. Choom™ will provide an amazing experience for customers, and bring style, sophistication and fun to the cannabis market with through our Choom™ stores.
www.choom.ca

REACH FOR YOUR FLOWER.

Flower Power Cannabis Pharms Inc. is a Saskatchewan-based retail brand experience company keenly positioned to inspire a new breed of cannabis consumer. The company has been created to authentically appeal to those looking at the consumption of cannabis as more of a ‘WHOLISTIC’ choice, rather than “medical” or “recreational”. Returning to the roots of this special flower and connecting consumers with its inherent benefits is exactly where Flower Power is positioned to flourish and bloom!
https://flowerpowerpharms.ca

“Chris Bogart”
President & CEO

Cautionary Statement:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking information
This news release contains forward-looking information relating to the Company’s proposed activities and other statements that are not historical facts. Forward-looking information relates to management’s future outlook and anticipated events or results, and include statements or information regarding the future plans or prospects of the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. These factors include risks and uncertainties associated with the results of diligence investigations, developments in the cannabis sector, delays resulting from or inability to obtain required regulatory approvals and ability to access sufficient capital from internal and external sources, reliance on key personnel, regulatory risks and delays and other risks and uncertainties discussed in the management discussion and analysis section of the Company’s interim and most recent annual financial statement or other reports and filings, including the Company’s Listing Statement, made with the applicable Canadian securities regulators. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information.

SOURCE Choom Holdings Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/March2018/28/c2652.html

Choom Holdings Inc., Chris Bogart, President & CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.caCopyright CNW Group 2018

Source: Canada Newswire (March 28, 2018 – 8:00 AM EDT)

The post Choom™ Signs Letter of Intent to Acquire Late Stage Saskatchewan ACMPR Applicant and Retail Brand appeared first on CannabisFN.

Lexaria Biosciences Engages CFN Media to Broaden Investor Awareness

Written by Ryan Allway on Mar 27, 2018

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has engaged CFN Media to conduct a 3-month investor and market visibility program to begin on March 28, 2018.

“Lexaria has become a leading innovator of cannabinoid delivery systems”, said Frank Lane, President of CFN Media. “The company’s DehydraTECH™ technology helps improve the bioavailability, absorption and taste of cannabinoids by encapsulating them in a lipid layer. We’re excited to be working with the company again as they expand their IP portfolio and commercialize these technologies.”

”We are pleased to be working again with CFN Media with their expertise in conveying the Lexaria story to as broad of a mainstream and cannabis-focused audience as possible,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “2018 is going to be a breakout year for Lexaria and CFN Media will ensure that everyone is reliably informed.”

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to attract high-quality investors to Lexaria Bioscience Corp. while elevating the company’s financial brand.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

About Lexaria Biosciences Inc.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.

The post Lexaria Biosciences Engages CFN Media to Broaden Investor Awareness appeared first on CannabisFN.

High Hampton: Three Pillars to Success in California’s Cannabis Industry

Written by Ryan Allway on

California is experiencing a ‘green rush’ following the legalization of adult-use cannabis with Proposition 64 and the roll out this year. According to BDS Analytics, the state’s retail cannabis market is projected to reach $3.7 billion by the end of this year and increase to $5.1 billion in 2019 as more dispensaries come online. There are many opportunities in the space, but some are better positioned than others to capitalize on the market over the near-term.

High Hampton Holding Corp. (CSE: HC) (FSE: 0HCN) has focused its efforts on three pillars to success: Building an experienced management team and board, developing an innovative business model to power long-term shareholder value, and executing on its vision.

Experienced Management Team

Many cannabis investments are businesses that pivoted from unrelated areas into the cannabis sector with little or no experience behind the wheel. In some cases, the teams behind these companies may have experience in one area, such as cultivation, but lack expertise in other areas that are necessary for success, such as regulations or finance. Investors should seek out companies with a mix of high-quality experience across the board.

High Hampton has a tremendous amount of experience in cannabis, political, legal, and the capital markets. CEO David E. Argudo is an elected city official with over eight years of experience consulting with municipalities looking to develop policies for cannabis. In addition to pioneering local cannabis tax measures in California, he has over 26 years of experience in pharmaceutical, cancer research, real estate, and mortgage financing.

President Richard Polanco is a former California State Senate Majority Leader and Founder of the California Latino Legislative Caucus in 1990. After spending a career advocating for medicinal cannabis in the state, he was an active proponent for Proposition 64 in 2016. The VP of Corporate Finance & Director, Christian Scovenna, and Chief Financial Officer & Director, Fiona Fitzmaurice, also bring tremendous financial and capital markets expertise to the team.

In mid-March, the company announced the addition of Paul Mann as Chief Operating Officer to support the next phase of aggressive business growth. Mann is a seasoned executive that has managed and successfully exited nine start-ups on three continents. With his successful track record and established business network, he is well-equipped to help the company organically grow its existing operations and pursue new acquisitions in the future.

Innovative Business Model

California is the largest legal cannabis market in the world with nearly 40 million residents and over a million medical cannabis patients. In fact, the market is estimated to be nearly seven times the size of Canada’s medical market and represents almost a third of North America’s legal cannabis industry. The state also attracts more than 260 million tourists each year that spend over $120 billion in the local economy.

Figure 1 – California’s Legal Cannabis Industry – Source: New Frontier Data & Arcview Market Research

The passage of Proposition 64 in November of 2016 did a lot more than just legalize adult-use cannabis – it created a framework for the cultivation and sale of all cannabis. Beginning on January 1, 2018, all cultivation of cannabis required municipal and state permits to legally operate. Many current growers do not meet the standards for these certifications and the state has been increasingly aggressive in shutting down non-compliant operations.

The supply of zoned and permitted areas to cultivate cannabis are in high demand and scarce, while many experienced cultivators have struggled to raise capital. High Hampton aims to purchase land and buildings in these zones to engage in royalty and leasehold agreements with tenants. In addition to consolidating the industry on its properties, the company aims to provide capital, compliance, licensing, and management consulting to brands and operators in California.

Initial Project in Place

Coachella is one of the most exciting municipalities in California to embrace the legal cannabis industry. Located about 30 miles east of Palm Springs, 72 miles east of Riverside, and 130 miles east of Los Angeles, the city was one of the first to pass an ordinance allowing the cultivation, processing, distribution, and testing of cannabis. The city has already approved over 120 acres and issued conditional use permits to several companies in the space.

High Hampton’s 100%-owned CoachellaGro asset is a 10.8 acre property located in the Coachella Cannabis Zone. Despite paying just $176,000 per acre in a transaction valued at $1.9 million, comparable land packages with a conditional use permit are valued at upwards of $5.5 million. Management is in the process of securing these conditional use permits (CUP) after submitting initial paperwork during the fourth quarter of last year.

The company’s management team believes that the permit will be awarded in the near-term and hopes to begin construction during the second quarter. Initial greenhouse facility construction will begin this year and initial cultivation could start as early as the fourth quarter of this year. By working with existing growers, the company is able to capitalize on an existing customer base and avoid the learning curve associated with new growers.

It’s also worth noting that the company has overcome many key hurdles facing legal operators. For example, energy costs tend to be a major concern among cultivators, but the company’s greenhouse plans use 65 percent less electricity than traditional greenhouses. This is done by combining natural sunlight with artificial lighting and ensuring that the entire environment is semi-sealed and tightly controlled.

Looking Ahead

High Hampton Holding Corp. (CSE: HC) (FSE: 0HCN) represents a compelling investment opportunity in California’s burgeoning cannabis industry. With a compelling land package in place, the company is well positioned to capitalize on the opportunity to work with existing cultivators and consolidate the state’s cannabis industry. Investors may want to take a closer look sooner rather than later given its ambitious timeline.
For more information, visit the company’s website or download their investor presentation.

Disclaimer

The post High Hampton: Three Pillars to Success in California’s Cannabis Industry appeared first on CannabisFN.

Delta 9 Signs LOI with Kalapa & CanPharma for Export of Cannabis to Germany

Written by Ryan Allway on

WINNIPEG, March 27, 2018 /CNW/ – DELTA 9 CANNABIS INC. (TSXV: NINE) (“Delta 9” or the “Company”) is pleased to announce that the Company has signed a non-binding letter of intent (the “LOI”) with CanPharma GMBH (“CanPharma”) and Global Group Kalapa S.L. (“Kalapa”) for the exportation of medical cannabis to Germany.

Delta 9 Cannabis has signed a Letter of Intent to export medical cannabis to Germany. (CNW Group/Delta 9 Cannabis Inc.)

Manitoba-based Delta 9 is one of Canada’s oldest medical cannabis companies, being the fourth company in Canada awarded a License to Produce under the Access to Cannabis for Medical Purposes Regulations.

Kalapa is based in Barcelona, Spain and owns a number of subsidiary companies, including a cannabidiol extracts (CBD) production and distribution company and the Kalapa Clinic, the first European consultancy focused on medical co-treatment with cannabinoids. Kalapa is a joint venture partner with CanPharma, a Berlin-based firm that is attempting to acquire a cannabis import license for its operations in Germany.

Under the LOI, Delta 9 has agreed to export a minimum of 40 kilograms of cannabis a month (480 kilos per year) and an additional amount of cannabis extracts to CanPharma for sale to medical cannabis patients in Germany. The agreement would also commit Delta 9 to provide additional cannabis for the German market in such amounts as may be mutually agreed by the parties.

Delta 9 CEO John Arbuthnot says the agreement with Kalapa is part of the Company’s continual development of markets for its cannabis-related products. “We’ve successfully bid for a retail license in Manitoba, we’ve established ourselves in Alberta, we’ve acquired national distribution agreements, and now our focus is on establishing the Delta 9 brand abroad, beginning in Europe,” Arbuthnot said. “We feel very fortunate to be working with a pioneer in cannabinoid treatment in the European Union, and very much look forward to expanding our business together.”

Dr. Henrik Sprengel, CEO of Kalapa, says the Delta 9 partnership reflects the strategic importance that Kalapa assigns the German market. “When medical cannabis was legalized in March 2017 only about 1,000 patients had a special authorization from the German cannabis agency (Bundesopiumstelle),” Sprengel said. “But estimates at the beginning of 2018 show rapid growth, with more than 30,000 cannabis patients existing in Germany today. Especially in Germany we have experienced a sharp increase in the number of requests for consultations with our doctors, so we are very keen to offer the best cannabinoid therapies possible to this growing client base.”

The LOI is a first step in establishing a binding formal export agreement with Kalapa and CanPharma. Before signing a formal export agreement, Delta 9 must: (i) acquire a Dealer License from Health Canada in order to legally export cannabis; (ii) acquire a Good Manufacturing Practices (GMP) certification; and (iii) satisfy an onsite audit of production practices by German authorities. In addition, the execution of the formal export agreement is subject to the completion of satisfactory due diligence by all parties.

About Delta 9 Cannabis Inc.
Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”. See more at http://delta9.ca

About Global Group Kalapa SL and CanPharma GMBH
Global Group Kalapa SL (www.kalapa-project.com) is a holding company based in Barcelona, Spain. It is owner of Kalapa Clinic – the first pan-European medical consultancy specializing in treatments with cannabinoids – as well as of KSK Labs, a producer and manufacturer of products based on CBD. Kalapa furthermore is a joint venture partner in other projects with medicinal cannabis, one of them being CanPharma (www.canpharma.de), an applicant for an import and distribution license in Germany.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) the execution of a formal export agreement with CanPharma and Kalapa; (ii) Delta 9’s acquisition of all required permits and licenses necessary to export cannabis products; and (iii) the size of the medical cannabis market in Germany. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that Delta 9’s currently contemplated expansion and development plans may cease or otherwise change, Delta 9’s production of cannabis may be lower than expected, Delta 9 may not obtain the required approvals from Health Canada, demand for Delta 9’s products may be lower than anticipated, Delta 9’s cost to produce its grow pods may be higher than expected and all other risk factors set forth in the filing statement of Delta 9 dated October 25, 2017 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE Delta 9 Cannabis Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/March2018/27/c5114.html

Gary Symons, Director of Communications, communications@delta9.ca, 250.300.9352Copyright CNW Group 2018

Source: Canada Newswire (March 27, 2018 – 5:30 AM EDT)

The post Delta 9 Signs LOI with Kalapa & CanPharma for Export of Cannabis to Germany appeared first on CannabisFN.

NanoSphere Health Sciences Awarded Breakthrough Patent for Disruptive Nanoparticle Delivery Platform

Written by Ryan Allway on

Landmark patent marks most significant advancement in over 25 years for non-invasive medical delivery systems

DENVER, March 27, 2018 /PRNewswire/ — NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF) is pleased to announce that its flagship subsidiary, NanoSphere Health Sciences, LLC, has been granted Patent No. 9,925.149—which covers the core technology behind the production of the NanoSphere Delivery System™—by the United States Patent and Trademark Office.

Photo Credit: NanoSphere Health Sciences

The research-proven NanoSphere Delivery System™, protected by this patent, is one of the most important advancements for the non-invasive delivery of biological agents in over 25 years. The patent broadly encompasses the formation and manufacturing of the NanoSphere Delivery System™ for the delivery of cannabinoids, pharmaceuticals, nutraceuticals, cosmeceuticals and other biological agents.

NanoSphere’s groundbreaking NanoSphere Delivery System™ nanoencapsulates a broad range of bioactive compounds in a protective membrane, transporting them rapidly and effectively to the bloodstream and cells for greater efficacy. This delivery platform is a breakthrough in pharmaceutical, cannabinoid, nutraceutical and cosmeceutical supplement delivery. It makes the nanoencapsulated agents safer and more bioavailable, reducing adverse effects by delivering precise doses of smart nanoparticles to target sites.

“The granting of the patent for the NanoSphere Delivery System™ secures our position as a leader in advanced nanoparticle delivery,” said Robert Sutton, CEO of NanoSphere Health Sciences. “Major industries have the potential to be reshaped and reimagined by our next-generation technology.”

“NanoSphere’s patent claims and protects our core technology for the formation and manufacturing of lipid, structural nanoparticles, which is the NanoSphere Delivery System™,” said Dr. Richard Clark Kaufman, Chief Science Officer and inventor of the NanoSphere Delivery System™. “This patent extends to our 16 forms of lipid nanoparticle structures, which can be applied across healthcare sectors for vastly improved medical delivery.”

With the issuance of this patent, the NanoSphere will now have long-term market exclusivity over this delivery platform, with patent infringement prohibited. The company intends to license the patented NanoSphere Delivery System™ and proprietary manufacturing process to selected companies in its target industries to maximize commercialization. This patent allows NanoSphere to bring to the world the NanoSphere Delivery System™ through multiple product lines and platforms, such as the company’s cannabis brand Evolve Formulas’ transdermal, intranasal and intraoral applications and beyond.

For more information or media inquiries, contact Emily Kielthy at emily@rosengrouppr.com or 646-695-7045.

On behalf of the Board:
Robert Sutton, Chairman & CEO, rsutton@nanospherehealth.com

Investor Contact:
David Sutton, President & COO / dsutton@nanospherehealth.com / 303.887.9300
Victor Goncalves, Executive Vice President / vgoncalves@nanospherehealth.com / 204-997-5517

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

NanoSphere’s Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences LLC, a subsidiary of NanoSphere Health Sciences INC (CSE: NSHS) (OTC: NSHSF), is the leader in nanoparticle delivery, a biotechnology company advancing the NanoSphere Delivery System™. NanoSphere’s patented core technology is changing the way biological agents deliver benefits.

NanoSphere’s disruptive platforms use smart nanoparticles to deliver cannabinoids, nutraceuticals, pharmaceuticals and over-the-counter medications in a patented process with greater bioavailability and efficacy for the cannabis, nutraceutical, pharmaceutical, cosmeceutical and animal health industries. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

View original content with multimedia:http://www.prnewswire.com/news-releases/nanosphere-health-sciences-awarded-breakthrough-patent-for-disruptive-nanoparticle-delivery-platform-300620137.html

SOURCE NanoSphere Health Sciences INC

Source: PR Newswire (March 27, 2018 – 9:00 AM EDT)

The post NanoSphere Health Sciences Awarded Breakthrough Patent for Disruptive Nanoparticle Delivery Platform appeared first on CannabisFN.

Abattis Announces $8 Million Financing and Successfully Closes First Tranche of Financing

Written by Ryan Allway on

VANCOUVER, British Columbia, March 27, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp.(the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it is has cancelled its previously announced non-brokered private placement for gross proceeds of up to $6 million, as described in the Company’s news release dated February 9, 2018, and is undertaking a new non-brokered private placement (the “Offering”) for gross proceeds of up to $8 million. The Company also announces that it has successfully closed the first tranche (the “First Tranche”) of the Offering through the issuance of 18,518,518 Units (defined herein) for gross proceeds of $5 million.

Pursuant to the Offering, the Company will issue up to an aggregate of 29,629,629 units (each, a “Unit”) of the Company, including those issued pursuant to the First Tranche, at a price of $0.27 per Unit. Each Unit will consist of one common share (a “Common Share”) of the Company and one common share purchase warrant (a “Warrant”), each Warrant entitling the holder to purchase one Common Share at an exercise price of $0.30 per Common Share for a period of twelve months from the closing date of the Offering. In the event that the Common Shares trade at a price on the Canadian Securities Exchange (the “Exchange”) (or such other exchange on which the Common Shares may be traded at such time) of greater than $0.50 per Common Share for a period of 10 consecutive trading days, Abattis may accelerate the expiry date of the Warrants by giving notice to the holders thereof (by disseminating a press release advising of the acceleration of the expiry date of the Warrants) and, in such case, the Warrants will expire on the thirtieth day after the date of such notice. The proceeds from the Offering will be used for general working capital.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante”

Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain information set out in this news release constitutes forward-looking information, which may include information relating to the proposed Offering and its use of proceeds. Forward-looking statements (often, but not always, identified by the use of words such as “expect”, “may”, “could”, “anticipate”, or “will”, and similar expressions) may describe expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by third parties. Forward-looking statements are based upon the opinions, expectations and estimates of management of the Company as at the date the statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. Those factors include, but are not limited to risks, uncertainties and other factors that are beyond the control of the Company, risks associated with the industry in general, rules and regulations relating to the cannabis industry, operational risks associated with development and production operations, delays or changes in plans and unanticipated costs and expenses, among others. In light of the risks and uncertainties associated with forward-looking statements, readers are cautioned not to place undue reliance upon forward-looking information. In particular, there is no assurance that the Offering will close in the manner or on the terms outlined above. Although the Company believes that the expectations reflected in the forward-looking statements set out in this news release are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward-looking statements of the Company contained in this news release are expressly qualified, in their entirety, by this cautionary statement. Except as required by law, we do not undertake to update any forward-looking statement contained in this news release.

Source: GlobeNewswire (March 27, 2018 – 7:00 AM EDT)

The post Abattis Announces $8 Million Financing and Successfully Closes First Tranche of Financing appeared first on CannabisFN.

Micron Waste Technologies to Present Plan for Cannabis Waste Disposal

Written by Ryan Allway on

OTTAWA, March 27, 2018 /CNW/ – The Senate Standing Committee on Agriculture and Forestry will hear testimony regarding cannabis disposal and its effects on the environment from Micron Waste Technologies Inc. President Alfred Wong and Board Member Cam Battley, who is also Chief Corporate Officer of Aurora Cannabis Inc. The testimony is expected to cover current and future cannabis waste disposal issues, including:

Disposal of illegal cannabis cultivated for the black market
Projections for the growth in cannabis waste, post-legalization
Canadian innovation in agriculture technology and new environmentally-friendly disposal methods

Micron Waste Technologies Inc. (CNW Group/Micron Waste Technologies Inc.)

Date	Tuesday, March 27, 2018

Time	6 pm EDT

Location	Room 2, Victoria Building, 140 Wellington Street

About Micron Waste Technologies

Micron Waste Technologies Inc. (CSE:MWM) (OTC:MICWF) (Frankfurt:7FM2) is a Canadian innovator in organic waste management. The company has developed novel technologies to extract clean water from organic food and cannabis waste, servicing the grocery, cannabis cultivator and restaurant sectors.

In January 2018, Micron finalized a collaboration agreement with Aurora Cannabis Inc., a leading Canadian licensed cannabis producer (“Aurora”) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) for the treatment of organic waste generated in the cultivation and production of cannabis products.

SOURCE Micron Waste Technologies Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/March2018/27/c1324.html

Karen Lauriston, Micron Waste Technologies, karen@micronwaste.com, +1.905.691-1185, www.micronwaste.comCopyright CNW Group 2018

Source: Canada Newswire (March 27, 2018 – 7:33 AM EDT)

The post Micron Waste Technologies to Present Plan for Cannabis Waste Disposal appeared first on CannabisFN.

Quadron Cannatech Begins to Ramp Up Revenue

Written by Ryan Allway on Mar 26, 2018

The Canadian cannabis industry is projected to reach C$22.6 billion in size over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis nationwide. While cannabis flower has generated the most sales to date, the fastest growing subset of the market is cannabis oils and extracts. Mackie Research believes that Canadian cannabis oil consumption will grow from just 284 liters in 2015 to more than 562,600 liters by 2020.

Quadron Cannatech Corporation (CSE: QCC) is a developer of cutting-edge cannabis extraction equipment that has seen strong interest following the recent MJBiz Conference in Las Vegas and the Lift Expo in Vancouver. With a very small footprint and minimal energy requirements, the BOSS CO2 Extraction System features proprietary max flow technology with advanced thermodynamics, automated features, and an exclusive plug-and-play design.

Massive Potential

Cannabis cultivators are always looking for ways to maximize revenue and profitability. Revenue growth is often a function of raw production capacity, but increasing profit margins can be trickier in an increasingly competitive industry. Cannabis flower is quickly becoming commoditized as a growing number of cultivators come online, which has led to a move towards cannabis oils and extracts that are used in applications like vape pens and edibles.

The challenge for many cultivators is finding a way to easily start producing cannabis oils and extracts. Often times, cannabis extraction equipment is expensive and difficult to install and operate, which makes it intimidating and cost-prohibitive for many smaller producers. Older and more expensive systems also have slower extraction times, which translates to less revenue potential for cultivators as they try to efficiently scale up their production.

The BOSS CO2 Extraction System is faster than many traditional machines. In fact, the complete cycle turnaround is just six hours, which includes four hours of extraction and two hours for decompression and cleaning, compared to upwards of eight to twelve hours for traditional extraction equipment. The system can also be installed and operational within hours with little more than an electrical outlet and a small space to put the machine.

In addition to the BOSS, the company manufactures vape pens and other consumption devices that can be branded for clients of the BOSS extraction equipment. Cultivators can purchase the extraction equipment, generate their own cannabis oil, and then sell branded vape pens with cartridges containing that oil to generate high margin recurring revenue. The company’s engineering team also provides consulting services to cultivators and other parties.

Accelerating Revenue

Quadron Cannatech recently announced the sale of two BOSS CO2 Extraction Systems to an authorized grower located in the Fraser Valley of British Columbia. The move comes about two months after the company closed a C$5 million financing, consisting of $0.70 units including one common share and one purchase warrant, that provided working capital to meet growing demand from customers following two successful trade shows in the U.S. and Canada.

“Quadron is well capitalized following the recent equity raises, along with the exercise of warrants,” said CEO Rosy Mondin in a recent press release announcing the two new sales to an authorized grower in British Columbia. “We have enough capital to not only service existing demand for the BOSS from interested parties, but also the capital to proceed with the development of new equipment. 2018 will be a milestone year for Quadron.”

Last month, the company also announced increasing sales of its next generation custom cartridges and vape pen consumption devices. These ancillary products and services are fully integrated with its equipment and laboratory environments, enabling its customers to quickly launch branded products into both medical and recreational markets.

Looking Ahead

Quadron Cannatech Corporation (CSE: QCC) represents a compelling investment opportunity. After raising capital in January, the company is rapidly scaling up production to meet strong demand from customers from trade show appearances. Its ancillary products are also quickly picking up steam, which could set the stage for recurring revenue over time. Investors may want to take a closer look at the stock given these catalysts.
For more information, visit the company’s website at www.quadroncannatech.com.

Disclaimer

The post Quadron Cannatech Begins to Ramp Up Revenue appeared first on CannabisFN.

Puerto Rican Alzheimer’s Patients to Be First in U.S. to Obtain Cannabis-Based Relief

Written by Ryan Allway on

BETHESDA, Md. and SAN JUAN, Puerto Rico, March 26, 2018 (GLOBE NEWSWIRE) — India Globalization Capital, Inc. (NYSE American:IGC) – Alzheimer’s patients in Puerto Rico will be the first in the United States to obtain Hyalolex, IGC’s proprietary cannabinoid based formulation aimed at relieving many of the symptoms of Alzheimer’s Disease, such as agitation, anxiety, sleep disorder, as well as caregiver distress, among others. Pursuant to an agreement between IGC and DaMa Pharmaceutical and its affiliates, Hyalolex will be on the shelves in April, and available to patients in ten of Puerto Rico’s 30 dispensaries, including the two premier dispensaries in San Juan, the largest city in Puerto Rico. Under the licensing terms DaMa will help produce Hyalolex in Puerto Rico, and market Hyalolex to medical dispensaries and end users. Hyalolex will be prescribed as a liquid supplement in twice-daily doses for mild to moderate Alzheimer patients, and thrice-daily doses for moderate to advanced patients.

“We are very pleased to work with the DaMa Pharmaceutical team to bring Hyalolex to Puerto Rico, which has a long history of developing premier pharmaceutical products,” said Ram Mukunda CEO of IGC. He noted that the Puerto Rican government has been a supporter of a comprehensive medical cannabis program. “We are proud to be a contributor to Puerto Rico’s economic development and to the wellbeing of its Alzheimer’s patients”, he said. According to alz.org, Hispanics are approximately one and one-half times as likely to have Alzheimer’s as non-Hispanic whites.

“This is a decisive step in delivering our cannabis intellectual property to patients, after many years of development. It is particularly important as part of our effort to establish a distribution network to productize our IP,” Mukunda said.

This partnership represents a significant opportunity to provide those afflicted with Alzheimer’s with potential relief from a very difficult diagnosis and ease the burden of their caregivers who attend to them. It also represents a significant opportunity to collect data on Hyalolex’s performance within a diverse patient set”, said Mukunda. IGC will deploy a QR code-based product assurance, information dissemination, and data collection system as a step towards a more robust block chain-based product assurance system.

About Alzheimer’s Disease:

Alzheimer’s Disease (AD) is a form of dementia. It is known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion. AD currently affects more than 5.3 million Americans and over 65% of AD patients are women. Over the next 20 years, the number of those afflicted with the disease is expected to double. The forecast is staggering, considering that to date, no effective cure has been found.

About IGC:
IGC has two lines of business. In addition to its cannabis pharmaceutical business, it also operates a legacy infrastructure and commodity trading business. Hyalolex is the Company’s lead product but it is in various stages of development of other cannabis-based medical products. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry including transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA). The Company is based in Maryland, USA.

For more information please visit www.igcinc.us; www.igcpharma.com; www.hyalolex.com. Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

About DaMa Pharmaceutical:
DaMa Pharmaceutical LLC is a Puerto Rico based Clinical Research Organization (CRO) providing clinical trials, manufacturing, and distribution of cannabis based medicine through licensed growers and dispensaries.

Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998

The post Puerto Rican Alzheimer’s Patients to Be First in U.S. to Obtain Cannabis-Based Relief appeared first on CannabisFN.

Segra International Engages CFN Media to Support its Go-To Market Strategy

Written by Ryan Allway on

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that Segra International has engaged CFN Media to conduct a 6-month pre-public and public markets investor visibility program to begin on March 26, 2018.

“Segra International is a biotechnology company that specializes in cannabis micropropagation, commonly known as tissue culture”, said Frank Lane, President of CFN Media.” This process replaces traditional cloning from mother plants with rapid, sterile production of robust and healthy plantlets. It generates exact copies of the original plant without the risk of pathogens and other issues that can plague cultivators. The company is poised to go public on the Canadian Securities Exchange (CSE) in the fall of 2018.

Segra recently announced an agreement with Hydropothecary Corporation (TSXV:THCX) to incorporate Segra’s micropropagation technology into their production process which will allow Hydropothecary to significant scale up rapidly to serve the growing medical and recreational cannabis markets.

“Segra is executing its plan to build micropropagation nurseries in both Canada and California capable of producing millions of disease free plant starts for licensed producers” said Todd McMurray CEO of Segra.

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to attract high-quality investors to Segra International while elevating the company’s financial brand.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

About Segra International

Segra is a plant biotechnology company that specializes in industrial-scale cannabis plant micropropagation. The company is developing industrial-scale cannabis micropropagation laboratories to produce healthy, robust plantlets for licensed cannabis producers globally. Segra has assembled a world-class team of specialists in the areas of plant tissue culture, agronomy, molecular genetics, regulatory compliance, and corporate finance. The Segra team includes Dr. Sma Zobayed, Segra’s Director of Micropropagation. Dr. Zobayed is a world-renowned micropropagation specialist who has successfully micropropagated over 500 species of plants including cannabis. Dr. Zobayed has successfully developed a protocol for true-to-type cannabis micropropagation (including 4 – 7 x multiplication of plant stock over a 30-day period). Segra will help its clients improve product quality, rapidly expand operations, decrease liabilities associated with pest and disease, and increase profits.

Forward Looking Statements

Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “expect”, “seek”, “endeavor”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made and involve significant known and unknown risks, uncertainties and assumptions which would cause actual results or events to differ materially from those presently anticipated. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to: (i) general business risk and liability; (ii) reliance on licenses; (iii) reliance on facilities; (iv) limited operating history; (v) unfavorable publicity or consumer perception; (viii) management of growth; (viii) reliance on management; (ix) conflicts of interest;; (x) limited market for securities; (xi) liquidity risk; (xiii) regulatory risks; (xiv) environmental and employee health and safety regulations; (xv) changes in laws, regulations and guidelines; (xvi) restrictions on sales and marketing; (xvii) competition; (xviii) risks inherent in an agricultural business; (xix) vulnerability to rising energy costs; (xx) product liability; and (x) operating risks and insurance coverage. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this document. Investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this document are based upon what management of Segra currently believe to be reasonable assumptions, Segra cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Segra does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances. The foregoing statements expressly qualify any forward-looking information contained herein.

The post Segra International Engages CFN Media to Support its Go-To Market Strategy appeared first on CannabisFN.

Pivot Pharmaceuticals Makes Strategic Entry Into California Cannabis Market, Announces Listing on Frankfurt Stock Exchange

Written by Ryan Allway on

VANCOUVER, March 26, 2018 /PRNewswire/ – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”), is pleased to announce that the Company has successfully completed the integration of its California subsidiary, ERS Holdings Ltd., under the guidance of Mr. Patrick Rolfes, President of Pivot Pharmaceuticals USA. Mr. Rolfes continues to surround himself with proven, well-respected and experienced leaders in the scientific, legal, financial, and marketing and branding fields. As Pivot prepares for product launch in California in 2018, a consumer-facing brand is being developed for the entire company and will be unveiled in the coming weeks. New websites and marketing materials for our various subsidiaries are also under development. A product list based on our industry-leading and patented bio-cannabis formulation and delivery technologies will be available for consumers and retailers in the coming months.

The Company also wishes to announce that it has secured a listing on the Frankfurt Stock Exchange (“FSE”) and has commenced trading under the symbol “NPAT”. The FSE is one of the world’s largest trading centres for securities, and the largest of Germany’s seven stock exchanges. The Company believes the listing in Germanywill give it greater exposure to a European-based investor audience, fuelling interest and liquidity in Pivot. The Company’s shares continue to trade on the OTCQB and the Canadian Securities Exchange.

Mr. Rolfes comments that “We are a health and wellness manufacturing company whose branded products incorporate patented scientific processes to bring cannabinoid-based derivatives to the market in discreet and consistent dosages with significant, targeted health benefits and superior bioavailability.” Mr. Rolfes added that “Pivot’s consumer-facing brands, backed by our patented technologies and formulations, will provide health conscious consumers with natural edible and topical cannabis products delivering exceptional targeted results which will quickly differentiate Pivot in the cannabis space.”

A report from the cannabis industry research firm BDS Analytics estimates sales of cannabis in California to hit USD $3.7 billion by the end of 2018 alone, and predicts that number will increase to USD $5.1 billion in 2019 as more dispensaries come online. For comparison, beer sales in the state hit USD $5 billion in 2017, according to industry research group IBIS World. California, the world’s sixth largest economy with a population of close to 40 million, will form a massive portion of the total market for cannabis in North America.

Dr. Patrick Frankham, Pivot’s CEO, states “As the Company prepares for legalization of cannabis in Canada, we continue to expand our business operations in the US market on a state-by-state basis, where regulations permit. California alone has a population four million people higher than Canada and the potential cannabis market size speaks for itself. During recent strategy sessions with Pivot USA, we finalized plans for Mr. Rolfes and his experienced team to launch Pivot’s consumer-facing brands through Pivot’s wholly-owned California licensed manufacturing facility, coming online later this year. Creating value for shareholders is of the utmost importance and I am confident that their investment will be rewarded in the weeks and months ahead.”

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology. BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc. or Pivot Green Stream Health Solutions Inc. or Pivot Pharmaceuticals USA Inc., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

SOURCE Pivot Pharmaceuticals Inc.

Source: PR Newswire (March 26, 2018 – 3:05 AM EDT)

The post Pivot Pharmaceuticals Makes Strategic Entry Into California Cannabis Market, Announces Listing on Frankfurt Stock Exchange appeared first on CannabisFN.

FinCanna Capital Corp. Comments on the Passage of the U.S. Consolidated Appropriations Act 2018 Retaining State Medical Marijuana Protections

Written by Ryan Allway on

Act Continues Protections for the Implementation of State Medical Marijuana Programs

VANCOUVER, British Columbia, March 26, 2018 (GLOBE NEWSWIRE) — FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (OTCQB:FNNZF) provides the following comments regarding passage in the USA of the “Consolidated Appropriations Act, 2018” a $1.3 trillion-dollar spending bill, which continues protections for the implementation of state medical marijuana programs through fiscal year end, September 30, 2018.

FinCanna welcomes this positive development and will continue to monitor any changes in the U.S. legal regime.

The United States Congress previously used a rider provision in the FY 2015, 2016, and 2017 Consolidated Appropriations Acts (formerly the Rohrabacher-Farr Amendment) to thwart the federal government from using congressionally appropriated funds to prevent states from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana. The 2018 appropriations protection, now known as the “Leahy Amendment,” continues this provision to 46 states, the District of Columbia, Guam, and Puerto Rico, with the exclusion of Idaho, Kansas, Nebraska, and South Dakota. The 2018 spending bill also continues existing provisions shielding state industrial hemp research programs from federal interference; however, it provides no protection for state-legal adult-use businesses or consumers. Although impermanent at this time, it is critical that Congress continue to include these temporary protections until comprehensive policy reform can be achieved.

Andriyko Herchak, CEO and Director of FinCanna states, “Our business has always been focused on financing top-tier companies in the licensed medical cannabis industry. We remain focused on the medical cannabis markets in States covered by this Act and believe this gives us a strong competitive edge in advancing the business to create strong shareholder value.”

As announced on January 15, and March 19, 2018, Cultivation Technologies Inc. (“CTI”), a portfolio company of FinCanna, took over direct operations of its Extraction Facility operating at its site in Coachella, California and CTI has the rights to 100% of the production capacity. CTI is quickly advancing towards commercialization and ramping revenue at the Extraction Facility from which FinCanna is entitled to receive 50% of the profits.

This Extraction Facility can currently process an estimated 6,000 pounds of biomass per month translating to approximately 3.7 million grams of raw oil per year. CTI has the ability to add an additional extraction machine and fractional distillation and winterization equipment. This would result in additional capacity to process 3,000 pounds of biomass per month and the ability to service third-party vaporizer, winterization and distillation customers at a scale of approximately 100,000 grams of finished product weekly.

About Cultivation Technologies
Cultivation Technologies, Inc. provides infrastructure, technology, and branding to the licensed medical cannabis industry. The first major project for the company is in Coachella, California, which will span 6-acres featuring cultivation centers, extraction and manufacturing facilities, a testing lab, a distribution hub, and a centralized processing center. For more information, visit www.CultivationTech.com.

About FinCanna Capital Corp.
FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues. FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California. For additional information visit www.fincannacapital.com and FinCanna’s profile at www.sedar.com.

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Forward-Looking Information
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about CTI’s future production and how the developing U.S. legal regime will impact the cannabis industry. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

The post FinCanna Capital Corp. Comments on the Passage of the U.S. Consolidated Appropriations Act 2018 Retaining State Medical Marijuana Protections appeared first on CannabisFN.

CFN Media – Exclusive Look into Dope Media’s Growth Trajectory

Written by Ryan Allway on

Dope Magazine is a premier lifestyle publication targeting the burgeoning cannabis industry. Since printing its inaugural issue in 2011, the company has become a leader in facilitating purposeful and relevant conversations across not only cannabis but also gender, race, politics, family, and culture – with the ethos DEFEND. The company aims to continue to illuminate issues that deserve attention and must be addressed in society.

CFN Media recently spoke with Dope Magazine CEO George Jage to discuss the company’s recent developments and long-term goals.

In the interview, Mr. Jage discusses the company’s impressive 90 percent year over year revenue growth and the founding team’s sheer grit and hustle to make things happen. He also discusses his role in bringing the underlying infrastructure to the business to set a stage for future organic growth, geographical expansion, and redesigning the consumer cannabis event experience.

For more information, visit the company’s website at www.dopemagazine.com.

The post CFN Media – Exclusive Look into Dope Media’s Growth Trajectory appeared first on CannabisFN.

Maricann Announces Phase One of Its Canadian Expansion is Ready to Grow Ahead of Schedule

Written by Ryan Allway on Mar 23, 2018

TORONTO, March 23, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI) (FRANKFURT:75M) (OTCQB:MRRCF) (“Maricann” or the “Company”), is pleased to announce that on March 20, 2018 the Company received an occupancy permit from Norfolk County for Phase One of its new grow facility in Langton, Ontario. The Company is now ready to begin cultivation in its Canadian expansion subject to receipt of Health Canada approval. Phase One is expected to increase the Company’s annual growing capacity to 25,000 kg of dry cannabis flower per year. Phase One is the first 217,000 square feet of a planned 942,000 square foot facility.

Ben Ward, CEO Stated, “We continue progress, executing against our strategy, ahead of the published deliverable date. Occupancy of our new Langton facility granted by Norfolk County is a demonstration of our continued commitment to all aspects of our business. We would like to thank Jeff Ayotte, our VP Infrastructure and his team for delivering the first section of our expansion, ready to produce and move into this next life cycle of the Company.”

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada, and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, capable of producing 95,000 kg of dry cannabis flower per year to support existing and future patient growth.

For more information about Maricann, please visit our website at www.maricann.com

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Forward Looking Information

Certain statements in this press release contain forward-looking statements, including with respect to the Company’s timeline for its expansion and plantation activities, positioning in the recreational cannabis market and future production capacity, which can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, “targeted” or any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. Management cautions readers that the assumptions relative to the future events, several of which are beyond Management’s control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: adverse weather, uncertainties with respect to legalization of recreational cannabis; risks inherent to expansion project; fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition, as well as other risks discussed in its latest annual information form and other disclosure documents of the Company available at www.sedar.com. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.

CONTACT INFORMATION
Investor Relations:
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665

Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland

The post Maricann Announces Phase One of Its Canadian Expansion is Ready to Grow Ahead of Schedule appeared first on CannabisFN.

Delta 9 Cannabis Leaps Forward in Canadian Market

Written by Ryan Allway on

As full legalization of cannabis throughout Canada nears, licensed producers are increasing production and positioning themselves in provincial markets to take advantage of the increased demand. Delta 9 Cannabis Inc. (TSXV: NINE), the fourth licensed producer in the country and the only Manitoba-based LP holding a sales license, recently announced an agreement allowing the company to dramatically expand its production capacity over the next couple of years. Combine this with the news that Manitoba recently granted Delta 9 conditional approval for one of only four retail cannabis licenses in the province, and a picture of a potentially dominant player in the oft-overlooked prairies of Canada emerges.

Expansion Plans

Delta 9 currently operates an 80,000 square foot production facility, leasing both the land and the building in East Winnipeg, Manitoba. Part of the new agreement is a five-year lease with an option to purchase the existing facility for $6.25 million. The company anticipates exercising this option and purchasing the building in the next several days, a move which would provide stability while adding an asset to Delta 9’s books.

Additionally, Delta 9 now has the option of purchasing three buildings on an adjacent piece of land, totaling approximately 100,000 square feet of new production space with 47 acres of industrial land for future expansion. Purchase price would be $6.5 million, and the buildings would require a minor retrofit to meet Health Canada standards. Delta 9 anticipates purchasing these buildings following the acquisition of the original production facility.

Upon completion of the retrofit and necessary approvals, Delta 9 expects production levels to reach approximately 17,000 kilograms/year by the end of 2019. The company maximizes production space with its modular grow pods, stackable containers that also serve to limit crop loss in the event of disease or contamination. Delta 9 also takes advantage of Manitoba’s relatively low power costs combined with inexpensive labour to help increase margins.

Supply and Demand

Delta 9 currently sells all the cannabis it produces, to thousands of medical patients. The company even operates its own medical outlet, the Delta 9 Lifestyle Cannabis Clinic in Winnipeg. A national distribution agreement with Canopy Growth Corp. further widens the company’s reach, with its craft grown strains offered in Canopy’s Tweed Main Street online store. All of that is an excellent foundation, and Delta 9 plans to build a whole lot more on top of it.

The Manitoba Liquor and Lotteries Corporation estimates the retail market for Manitoba alone at somewhere between $300 million and $500 million per year, and the government is only allowing four groups to establish sales operations there. Delta 9, in partnership with Canopy Growth, is one of those four groups and already has a leg up on the competition with its existing Winnipeg outlet. To ensure adequate supply for the new market as it ramps up its own production, the company recently signed an agreement with Alberta-based Sundial Growers to provide up to 5,000 kilograms of dried cannabis and derivatives.

“We’ve committed to producing a baseline amount of product for the Manitoba market, and we are confident we can achieve those numbers,” said CEO John Arbuthnot. “However, we would like to exceed those projections in order to not only meet demand in Manitoba , but also meet or exceed our commitments to national sales under our CraftGrow agreement with Canopy Growth.”

Looking Ahead

While the retail rollout in Canada proceeds in legislative fits and starts, the national and provincial governments remain committed to full legalization in the very near term. Delta 9 Cannabis appears well positioned, both through its own place in the Manitoba market and through partnerships that provide national exposure, to capitalize on the vastly expanding legal cannabis market. Watch for further developments as legalization nears and Delta 9 continues its anticipated growth trajectory.

For more information please visit the company website at https://www.delta9.ca/

Disclaimer

The post Delta 9 Cannabis Leaps Forward in Canadian Market appeared first on CannabisFN.

The Future of Cannabis Health Lies in Collaboration

Written by Ryan Allway on Mar 22, 2018

Many physicians are hesitant to prescribe medical cannabis due to a lack of understanding about how it affects patients and what strains and dosages are appropriate. Without an effective feedback loop between patients and healthcare providers, the situation is unlikely to improve. The good news is that some companies are seeking to close the feedback loop.

Resolve Digital Health Inc.’s Resolve ONE™ smart inhaler represents a breakthrough in the medical cannabis industry and investors may want to take note sooner rather than later.

Click here to receive company updates and alerts regarding Resolve.

The Incomplete Feedback Loop

One of the issues facing physicians is the lack of accurate feedback and information from their patients. A doctor may prescribe a treatment, but once the patient leaves the office, the doctor has no idea whether the patient picks up the prescription or uses it as directed. Even in the best case scenario of perfect patient compliance, there is usually no communication about the patient’s experience while following the prescription. Is the treatment working? How does the patient feel? Is there a potentially better solution to be tried prior to the next scheduled visit? A system streamlining a patient/doctor feedback loop would go a long way toward making treatments as effective and responsive as possible for each individual.

Medical cannabis has been shown to effectively treat many conditions, but there are few robust clinical trials to guide physicians’ decisions. Without any clinical trials or shared data, many physicians have a hard time knowing which cannabis strains to prescribe to a patient. It’s also challenging to follow up with the patient over time to personalize the treatment. This incomplete feedback loop has become a major barrier for medical cannabis therapies.

Closing the Feedback Loop

Resolve Digital Health’s smart inhaler, the Resolve ONE™ is designed to close the feedback loop between patients and doctors by providing a tool that monitors treatment and shares data. In addition to providing a metered dose to the patient, the device captures data on medical conditions, prescriptions, family history, lifestyle, and effectiveness per dose. This information enables patients and their physicians to monitor efficacy and continuously improve treatment. The data is stored and, at the patient’s discretion, can be shared with doctors, pharmacists, and other caregivers, bringing collaborative healthcare to the cannabis industry. Doctors can see how a patient is responding to treatment and adjust as needed.

Doctors can also leverage data from one patient to inform how to better treat other patients. Rather than guessing what strains work best, they can look at their other patients and see that a certain strain and dosage tend to work best. This reduces the amount of trial-and-error involved when prescribing medical cannabis and helps improve the overall patient experience, while reducing the physician’s need to spend time trying to extract information from patients.

By bringing collaboration back to healthcare, the patient can be sure that they’re receiving the best possible treatment at all times.

Click here to receive company updates and alerts regarding Resolve.

Leveraging Consumer-Generated Data

Resolve’s long-term plans are to use the data generated from its Resolve ONE™ inhaler to help improve the medical cannabis industry on a large scale.

Patients will have the opportunity to anonymously share information about the medical condition for which they are being treated and which strains and doses worked best for them. Licensed producers can use this data to improve their product offerings and effectiveness. For instance, the data may show that one strain works better for opioid-replacement than another. The LP may decide to focus their growing efforts on the more effective strain and market that strain to patients and physicians based on the hard data. The same goes for specific concentrates of CBD, THC, and other cannabinoid compounds.

Healthcare industry partners can leverage the same data to aid research on the efficacy of specific strains’ medicinal value when conducting trials. There’s no doubt that clinical trials are needed to push the industry fully into mainstream medicine and the data collected from the Resolve ONE™ is a key step in that process. By identifying the most promising starting point, researchers can minimize trial-and-error and focus on developing optimal therapies.

Resolve Digital Health is also initiating its own clinical trial program in the hopes of pushing the industry forward. Utilizing the Resolve ONE™ inhaler, the company is investigating the efficacy of cannabis as a tool for pain management. The studies will examine cannabis as both a substitute for and an adjunct to opioid treatments. The company also plans to study cannabis as a treatment for a variety of other conditions, including sleep disorders, anxiety, depression, and PTSD.

Looking Ahead

Resolve Digital Health Inc.’s smart inhaler represents a breakthrough in the medical cannabis industry. With the potential to close the feedback loop, the device can help dramatically improve patient efficacy and make physicians more likely to prescribe the drug. The data generated from these activities can also help licensed producers optimize their growing and healthcare researchers optimize their clinical trials.

For more information, visit the company’s website at www.resolvedigitalhealth.com.

Disclaimer

The post The Future of Cannabis Health Lies in Collaboration appeared first on CannabisFN.

Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for “Composition of Matter” Cannabinoid Delivery

Written by Ryan Allway on

KELOWNA, BC / ACCESSWIRE / March 22, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces it has received a new Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) providing for “composition of matter” claims that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH™ technology for the delivery of cannabinoids. This is a significant addition to Lexaria’s existing manufacturing “method of use” patent rights previously granted.

“This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH™ technology,” said John Docherty, President. “This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed demonstrating its significant bioavailability performance enhancement properties.”

Under USPTO practice, there is no opposition period between allowance and issuance. The patent application number is 15/225,802, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” As has been Lexaria’s experience in the past, the Company expects the formal granting of the new patent within roughly one hundred days or less.

Lexaria has additional patent applications that remain within the USPTO process, of both the composition of matter and process varieties. Lexaria will continue to develop and strengthen its patent portfolio in the USA, Canada, and internationally and expects further patent awards this year. As its patent portfolio increases, Lexaria will be better able to commercialize its technologies and defend its intellectual property.

Lexaria’s patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredient (“API”) substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria’s patented technology. Lexaria’s long-term strategy is to partner with the world’s leading firms as they deliver best-of-class products to their existing large consumer groups.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH^TM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook http://tinyurl.com/y8vzcaam.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Lexaria Bioscience
Alex Blanchard,
Communications Manager
(778) 796-1897

NetworkNewsWire (NNW)
www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will, in fact, be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Bioscience Corp.

The post Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for “Composition of Matter” Cannabinoid Delivery appeared first on CannabisFN.

Future Farm Signs LOI with CEPG Consulting and Design Inc. to Create Elite New Cannabis & Hemp Strains in St. John’s, Nfld

Written by Ryan Allway on

March 22, 2018 / TheNewswire / Vancouver, British Columbia – Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce that it has signed a Letter of Intent (“LOI”) to acquire a 50% interest in and to enter into a definitive joint venture agreement with CEPG Consulting and Design Inc. (“CEPG”) of St John’s, Newfoundland. The joint venture is formed to begin operations for a cannabis and hemp breeding program under its previously announced joint venture with Rahan Meristem Ltd. (“Rahan”), a world renown global agro-biotechnology company incorporated in the State of Israel. The joint venture will operate out of both an existing building and 6,000 square feet of newly constructed laboratories.

CEPG is a Canadian corporation wholly owned by Snellen Holdings (1994) Co. Ltd. (“SHC”), based in St John’s, Newfoundland. SHC has been developing controlled environment plant growth systems since 1981. SHC will transfer ownership of land and a building located in St. John’s, Newfoundland, as well as a 48-ft trailer and its contents.

CEPG will apply for a dealer license from health Canada, which will enable research and development to begin on the growth of cannabis plants. Once licensed, the R&D facility will use state-of-the-art controlled environment equipment and techniques to create a research hub for the Rahan and Future Farm JV, which is expected to create valuable IP to be sold worldwide. The joint venture will develop, own and utilize Rahan’s proven and proprietary technology to mass-produce elite new strains of marijuana to fit various profiles required of the medical and legal use of this highly valuable and beneficial plant.

“We have toured this building and endorsed the plans to build new in-vitro and tissue culture labs on this site. We feel it’s the perfect facility for us to create elite new cannabis strains and are pleased with the partnership formed by Future Farm and CEPG,” says Ron Diner, CEO of Rahan. “We look forward to combining our technology and know-how with Future Farm’s experience in cultivating cannabis to produce elite strains for use in the booming medical and recreational marijuana markets.”

As part of the subject JV agreement, Rahan shall be responsible for providing the know-how and technology, as well as management and operation of the breeding program.

“We are thrilled to partner with Rahan Meristem, an esteemed leader in the agro-biotechnology industry, and now CEPG. The building in St. John’s allows us to get started on the permitting and growing of elite cannabis clones.” says Bill Gildea, CEO of Future Farm Technologies. “Rahan has shown long term dedication to producing elite clones of bananas, plantains and other plants for its customers worldwide. We are lucky to have Rahan’s desire to take its proven technology to work on producing the same results for cannabis and hemp. This is a very exciting time for Future Farm.”

Future Farm, Rahan Meristem and CEPG want to take this opportunity to publicly thank the following:

Provincially: These projects were made possible by our Hon. Premier, Dwight Ball, and The Government of Newfoundland Labrador. Our sincere thank you to our MHA The Hon. Bernard Davis, who supported us since the day he was elected. Our current Minister of Transportation and Works, The Hon. Steve Crocker, and his predecessor The Hon. Al Hawkins, who made time for us made this possible.

Federally: The complex Federal/Provincial land issues that had to be settled could not have been resolved without the determination of our MP Mr. Nick Whalen, and former Federal Minister responsible for PWGSC, The Hon. Judy Foote. Thank you all for the Federal / Provincial co-operation.

In consideration for the acquisition, SHC will receive CAD$150,000 in the form of Future Farm common stock valued at the closing price on the day prior to this press release, and the cash equivalent value of CEPG’s 1,940 shares in Canopy Growth Corporation, valued at the closing share price on the day the transaction closes and Mr. H. C. Snellen will receive CAD$50,000. An additional payment is expected to be issued to SHC in Future Farm stock equivalent to the dollar value of a second tranche of Canopy stock. All Canopy stock will remain with CEPG.

The Company also announces that the Board of Directors has approved the cancellation of 3,487,500 incentive stock options currently exercisable at $0.96CDN.

For further information, contact William Gildea, Director, at (888) 387-3761.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman & CEO

About Snellen Holdings:

Snellen Holdings and CEPG (controlled environment plant growth) are founding shareholders of Spot Therapeutics Inc. CEPG designed Spot’s 40,000 sq. ft. medical marijuana production facility in Fredericton New Brunswick. CEPG, then a wholly owned Subsidiary of Snellen Holdings was incorporated to be Spot’s horticulture department. Shortly after Spot received their “letter to build” approval from Health Canada, Canopy Growth Corporation bought Spot. CEPG is currently engaged as consultants for the Argentia Gold Corporation, an 80,000 sq. ft. medical marijuana LP applicant in Newfoundland Labrador. Future Farm is now a 50% partner in CEPG.

About Future Farm

The Company recently acquired the exclusive right to use a patented, augmented reality (AR) technology in the cannabis industry. As described in more detail above, the Company has decided to spin this asset off to its shareholders.

The post Future Farm Signs LOI with CEPG Consulting and Design Inc. to Create Elite New Cannabis & Hemp Strains in St. John’s, Nfld appeared first on CannabisFN.